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The first half of this thesis is focused on the development of a dissolving microneedle (MN) 
patch for polio vaccination. Poliomyelitis (polio) is a highly infectious disease with no 
cure. Thus, the most effective strategy to eradicate polio is by vaccination. We developed 
a dissolving microneedle patch for administration of inactivated polio vaccine (IPV) with 
improved thermal stability when compared with commercial liquid IPV. A combination of 
maltodextrin, D-sorbitol and fish gelatin in histidine buffer was found to best preserve IPV 
activity during MN patch fabrication and storage. After 1 month at 40 °C, IPV activity was 
< 10 % for all three serotypes in a commercial liquid vaccine formulation but was > 40 % 
for all three serotypes in MN patches. In addition, activity remained >40% after 2 months 
and > 20% after 1 year of storage at 40 °C for all three IPV serotypes based on D-antigen 
content measured by ELISA. Residual moisture content in MN patches measured by 
thermogravimetric analysis, glass transition temperature measured by differential scanning 
calorimetry, structural changes measured by X-ray diffraction and molecular interactions 
measured by Fourier-transform infrared spectroscopy showed changes in MN matrix 
properties but did not correlate with IPV activity changes during storage. We conclude that 
appropriately formulated MN patches can exhibit thermostability that could enable 
distribution of IPV with less reliance on cold-chain storage.  
The second half of the thesis is dedicated to the development of a simple MN patch for the 
collection of interstitial fluid (ISF) for diagnostic applications.  ISF that surrounds cells in 
tissues of the body is a novel source of biomarkers similar to blood but relatively 
unexplored due to limitations in sampling techniques.  To overcome difficulties in 
harvesting ISF, we developed a minimally invasive, rapid, simple-to-use and cost-effective 
method to collect ISF from the skin involving a MN patch. By pressing 650 µm long MNs 
at an angle just below the skin surface, blood-free ISF flowed through micropores to the 
skin surface and was absorbed into a thin strip of paper on the MN patch backing for 
subsequent analysis. An optimized method in rat skin in vivo was well tolerated and able 
 
 
to collect > 2 µl of ISF within 1 min. Brief skin pre-treatment with MNs followed by a 5 
min delay dramatically increased subsequent ISF collection by a mechanism believed to 
involve increased skin hydration. We demonstrated the suitability of our MN patch for 
therapeutic drug monitoring in ISF by showing similar vancomycin concentration-time 
profiles and pharmacokinetic parameters in the ISF and blood in rat in-vivo. We also, for 
the first time, detected polio specific neutralizing antibodies, and anti-polio IgG in ISF 
similar to blood in rats immunized with the polio vaccine. ISF collection using a MN patch 
has the potential to simplify access to biomarkers in ISF for research and future 





CHAPTER 1. INTRODUCTION 
This research presented in this thesis comprises of two projects. The goal of the first 
project was to develop a thermostable dissolving microneedle patch for Polio vaccination. 
The goal of the second project was to develop a paper based microneedle patch for 
collection of dermal interstitial fluid (ISF) to capture and detect a biomarker of interest. 
 
1.1 Microneedle patch for polio vaccination 
Polio is a highly infectious disease which can best be prevented by immunization [1].  
The two most common routes of vaccination are IPV (Inactivated Polio Vaccine) which 
is administered as an intramuscular injection and OPV (Oral Polio Vaccine) which is 
administered orally. IPV is the safer method of vaccination but has several drawbacks, 
such as the need for a trained medical personnel, a reliance on the cold-chain for 
transportation and storage, and a possibility of needle-stick injuries[2].  Dissolving 
microneedles (MN) are micron-scale structures that can be designed to painlessly pierce 
the skin and deliver vaccines or drugs [3-5]. The advantages being the possibilities of 
self- administration, cold chain removal and lack of biohazardous sharps waste. The 
development of thermostable dissolvable MN patch for IPV could prove to be very useful 
for better vaccination coverage in developing countries.  
The crux of this project was focused on fabrication and characterization of a dissolvable 
MN patch for polio vaccination which is thermally stable, mechanically robust, and 
 
 
biocompatible. The development work was specifically geared towards the following 
areas: 
a. Formulation optimization: finding the right combination and concentration 
of biopolymer (ex. silk fibroin and gelatin) along with other sugars or alcohols 
(ex. trehalose, sorbitol), buffer to stabilize dried IPV.  
b. Processing parameter optimization: Drying temperature and time during 
microneedle fabrication. 
The mechanical properties and long term thermal stability of the optimized MN patches 
were tested. Mechanistic studies were performed to correlate MN matrix properties to 
IPV activity using techniques such as Thermogravimetric analysis (TGA), Differential 
scanning calorimetry (DSC) and X -ray diffraction. 
 
1.2 Paper based microneedle patch for collection of ISF 
 Rapid and reliable detection of a diverse set of biomolecules, such as metabolites, 
proteins and peptides are critical for disease management and regular health monitoring. 
Current diagnostic devices detect these biomarkers in body fluids such as blood, urine, 
saliva and sweat. Some of the issues with current diagnostic devices include the need for 
trained health care professional for blood collection by painful venipuncture, and need for 
large sample size.   ISF is an unexplored body fluid which does not clot and has been 
shown to contain many biomarkers of interest for systemic and dermatological analysis 
[6-8].  However, ISF is not widely used for diagnostic applications due to limitations of 
existing sampling technologies such as limited sample volumes, patient discomfort and 
 
 
need for sophisticated equipment. Hence, there is a need for an easy to use, reliable 
method for collection of microliters of ISF within minutes.  
This project was geared towards development of an easy to use paper based MN patch for 
collection of microliters of ISF within minutes. Factors affecting ISF collection were 
tested and the optimized MN patch was tested in rats in-vivo to collect ISF for detection 
of biomarkers of interest. Simplified access to biomarkers in ISF using a MN patch may 






CHAPTER 2. LITERATURE REVIEW  
2.1 Poliomyelitis 
 Poliomyelitis, often known as polio is a highly contagious disease caused by any 
one of the three serotypes, wild polio virus type 1(WPV1), type 2(WPV2) or type 
3(WPV3). Most of the infected people (~90%) are asymptomatic[9]. However, only in a 
small percentage of cases the virus enters the nervous system[10].  This can lead to 
paralysis of limbs and in some rare fatal cases, paralysis of respiratory system as well.  
Poliovirus is a member of the enterovirus subgroup, family Picornaviridae[11]. This 
means that polio virus is a transient inhabitant of the gastrointestinal tract and a small 
virus with an RNA genome enclosed in a protein shell called a capsid. It is known to 
infect via the fecal-oral route [12]. The Global Polio Eradication Initiative (GPEI) was 
established by the World Health Organization (WHO) in 1989 to spearhead the efforts to 
eradicate polio[13]. Thanks to GPEI’s continuous efforts, the number of polio cases have 
dropped from 350,000 in 1988 to only 22 reported cases in 2017[14].  WPV2 has been 
eradicated and has not been detected since 1999.  The Global Commission for the 
Certification of the Eradication of Poliomyelitis (GCC) certified WPV2 as eradicated in 
September 2015. WPV3 was last detected in November 2012 in Nigeria. WPV1 is the 
only serotype that is currently endemic to three countries (Afghanistan, Nigeria, and 
Pakistan).  However, the WHO predicts that failure to eradicate this disease can cause as 
many as 200,000 new cases every year in 10 years[15]. 
2.1.1 Vaccine Delivery 
2.1.2  Current polio vaccine delivery routes 
 
 
There are two types of vaccines that protect against polio: IPV and OPV. IPV which is also 
known as “Salk vaccine” is an intramuscular injection of inactivated (killed) polio vaccine 
of all three serotypes[16]. OPV which is also known as “Sabin vaccine” consists of a 
mixture of live attenuated (weakened) polio viruses[17].  OPV is the vaccine of choice in 
developing countries because it is significantly cheaper, easy to administer, only requiring 
an oral delivery of 2 drops of vaccine[18]. The attenuated virus can then, infect the lymph 
tissues of the gut. This mimics the natural route of infection and generates a potent immune 
response. However, a major concern with OPV is the possibility of causing vaccine-
associated paralytic polio (VAPP)[19]. Another low risk is the possibility of a viral 
recombination of attenuated strain reverting to the wild type.  This is known as circulating 
vaccine-derived poliovirus (cVDPV). The risk of reintroducing polio in US led to the phase 
out of OPV from the childhood immunization schedule[20]. OPV was replaced by IPV in 
US and UK in 2000 and 2004 respectively[21].  
The biggest drawbacks with IPV are the need for intramuscular (IM) injection [22] and the 
high cost of the vaccine[16]. The current IPV formulation requires multiple doses for a 
potent immune response[23].  Two doses of IPV provide 90% immunity to all three polio 
serotypes and 3 doses provides at least 99% immunity.  
IPV requires that healthcare personnel administer the vaccine, and even with the training 
healthcare personnel receive, needle-stick injuries are common.  These can lead to the 
exposure to unknown pathogens and the transmission of blood-borne infectious 
diseases[24].  Medical waste and safe disposal of sharps can pose problems especially for 
large scale campaigns [25]. Also, trained healthcare professionals many not be available 
especially in rural areas of developing countries. 
 
 
Patients can be hesitant to receive any treatment via an injection due to the pain of injection 
and needle-phobia.  This decreases patient compliance [26]. Disposal of used needles 
presents a hazard too. Also, IPV is currently formulated as a liquid (in medium 199)[27] 
and is stable for over a year at 4°C, but loses potency in only weeks at 25 °C or 37 °C [28].  
Hence, it is of great interest to develop an easy to administer, thermostable IPV 
formulation. 
2.1.3 Microneedle patches for vaccine delivery  
A novel method for vaccine delivery is by using MN patches. As a micron-scale device, a 
MN patch has the ability to penetrate the barrier layers of the skin in a minimally invasive 
manner[29].  
Skin is the largest and most accessible organ of our body. This makes it attractive for drug 
or vaccine delivery. Skin essentially consists of three layers: the epidermis, the dermis and 
the subcutaneous layer. The epidermis consists of the outermost layer, stratum corneum 
(SC) and the viable epidermis. SC is a 20 µm thick[30] layer made up of brick and mortar 
type flat dead corneocytes tightly joined by intercellular lipids. The viable epidermis (50-
100 µm thick) is avascular and consists of ten layers of randomly oriented living cells like 
keratinocytes and basal cells. The epidermis is rich in Langerhan cells which can help 
invoke an immune response[31]. 
The epidermis and dermis are separated by the basement membrane. The dermis is the 
thickest layer of the skin and has thickness ranging from 1-2 mm. The dermis has a water 
content of about 70%.  It is vascular, has hair follicles, sebaceous glands, sweat glands and 
 
 
lymphatic system. The dermis contains dendritic cells which are thought to induce cell-
mediated immune responses[32]. They have also been shown to enhance antibody 
production by B cells. The dermis also plays a role in inflammatory response and also 
provides nutrition to the epidermis.  
The subcutaneous tissue consists of the interstitial tissue and the adipose tissue[33]. It has 
water content similar to the dermis and its functions include preserving body heat and 
acting as shock absorber. 
Vaccines are typically made up of either whole virus particles or selected antigen subunits. 
They are macromolecules and do not passively diffuse across the SC easily. Traditional 
vaccine delivery by injection bypasses the skin’s immune system and delivers the antigen 
into the muscle or sub-cutaneous tissue. The premise behind using microneedle technology 
is that vaccine delivery can be significantly improved if the SC layer is breached [34]. The 
MN patch is designed to be long enough to penetrate the SC, but short and thin enough to 
avoid the blood vessels and nerves in the dermis layer. Hence, MNs have the unique 
advantage to be large enough to deliver almost any vaccine, but still be small enough to 
avoid pain, fear and the need for expert training to administer. MN patches have also been 
demonstrated to be patient-friendly and user compatible[35]. There is a potential for greater 
immunogenicity too because the vaccine is delivered in the epidermis region. 
There are various types of microneedles such as the solid microneedles, coated 
microneedles, hollow microneedles, dissolving microneedles and swellable microneedles. 
Zhu et al.  demonstrated that metal microneedles coated with inactivated influenza vaccine 
could immunize mice by simple skin insertion[36].  The group receiving MN patch had 
 
 
superior protection against a challenge with live influenza virus compared with mice 
receiving the same dose via an IM injection.  Other vaccines such as hepatitis C [37] and 
Bacillus anthracis[38] have also been delivered using coated steel microneedles.  
Further development of microneedle technology resulted in dissolving polymeric MN 
patches. Dissolving polymer MN patches are composed of a vaccine and other excipients 
such as stabilizers, adjuvants loaded in a water soluble, biocompatible polymer matrix. A 
variety of polymers such as polylactic-co-glycolic acid (PLGA), polyvinylpyrrolidone 
(PVP) and maltose [3,39,40] have been used for MN patch fabrication. The needles have 
been shown to be mechanically robust to penetrate the SC and dissolved by the ISF thereby 
delivering the vaccine.  An example of dissolving polymer microneedle is shown in Figure 
2-1.  
    
Figure 2-1: Example of a dissolving MN patch. A: Dissolving MN patch at high 
magnification. B: Pig skin after insertion and dissolution of a dye-containing MN 
patch. C: Side by side comparison of a dissolving MN patch to a US nickel coin. D: 
 
 
Dissolving MN patch before and after insertion. Image reproduced from Sullivan et 
al.[3]. 
Dissolving MN patches can be self-administered painlessly[41] with no sharps as waste. 
Dissolving MN patches have been used for various vaccinations such as measles[42] and 
influenza[43]. In the influenza vaccine study, Sullivan et al. encapsulated the vaccine in a 
PVP MN patch and deposited in the skin of mice. This resulted in a potent immune 
response that protected the mice against a lethal challenge.  
2.1.4 Current polio vaccine stabilization strategies 
Commercially available full human dose of IPV vaccine contains a trivalent dose of 40 D-
antigen units (DU) of type 1, 8 DU of type 2 and 32 DU of type 3 polio virus[44]. It is 
formulated in aqueous medium (Medium 199) along with other chemicals. 2-
phenoxyethanol, a glycol ether is used as preservative. Formaldehyde is added to inactivate 
the virus while antibiotics such as neomycin, streptomycin, polymyxin B are added to 
prevent bacterial contamination [43]. MgCl2 is currently used in the pharmaceutical 
industry to stabilize Sabin vaccine or OPV[45]. 
Other researchers have tried to stabilize polio virus (IPV/OPV) and increase thermal 
stability by addition of various stabilizing agents. Robinson et al. showed that 
lipolysachcharides (LPS) and peptidoglycan increased the thermal stability of Sabin 
serotype 1 by binding to the capsid protein[46].  Dorval et al. showed that fatty acids, in 
particular, lyotropic salts significantly stabilize poliovirus[47]. They also showed that 
amino acids such as L-lysine and L-arginine are effective in preventing heat inactivation 
of poliovirus[48]. Other groups showed addition of pirodavir[49], or replacement of water 
with deuterated water[50] were beneficial. However, all of these studies were performed 
 
 
in liquid formulations and on Sabin vaccine and may not be useful for MN patches, which 
are dried and use Salk vaccine. 
MN patch fabrication involves drying of the formulation for the formation of solid MNs. 
As the vaccine is removed from an aqueous environment, it undergoes changes that 
decrease its specific antigenicity[51]. Hence, sugars such as trehalose, or sucrose may have 
to be added to help maintain the environment necessary for the native structure of the 
biomolecule[52].  
Other researchers showed that virus particles can be encapsulated in silk or other proteins 
to prevent conformational changes and improve thermal stability[53] [54].  
Lyophilization is one of the oldest and commonly used technique for preparation of solid 
protein pharmaceuticals. However, this process can generate different types of stresses, 
such as solute concentration, formation of ice crystals, pH changes etc. Kraan et al. 
performed extensive excipient screening and developed a formulation containing sorbitol, 
MgCl2 and L-glutamic monosodium salt monohydrate (MSG) for stabilization of 
lyophilized IPV[55]. They also performed in-vivo studies and showed comparable 
immunogenicity to liquid IM injection when administered in a booster regime[56]. 
2.1.5  Motivation for research on MN patch for IPV administration 
Since 1988, the world has come very close to eradicating polio. Despite numerous efforts 
to simplify delivery of the polio vaccines, hurdles still exist. The requirement for trained 
medical personnel limits the reach of large-scale campaigns especially in the polio endemic 
countries. Necessity for cold chain to maintain vaccine stability can be burdensome too. A 
 
 
safe, thermostable, dissolving MN patch for IPV administration would represent a 
significant advance, removing many of the hurdles remaining in the eradication of this 
disease.  
2.2 Disease diagnosis and monitoring 
The analysis of body fluids is vital for the diagnosis and monitoring of a disease. An 
alteration in concentration or composition of a particular biomarker in a body fluids is used 
as an indicator of a physiological or pathological condition [57].  
Traditionally, diagnostic procedures are performed mainly by health care professionals 
during a doctor’s visit or in a hospital setting. Recent trend in diagnostics is the emergence 
of point of care diagnostics. Point of care diagnostics enables rapid diagnosis for efficient 
management of variety of conditions and diseases in a clinic, an ambulance or even at 
home. The point of care testing is an emerging trend in diagnostics and is driving 
innovation in global health [58].  
Many diagnostic devices detect changes in certain biomarkers. The measured response 
could be a physiological, biochemical, functional or a molecular interaction. 
Many biomarkers have been validated for monitoring and treatment of various disease. 
Detection of such markers at an early stage can lead to a prompt diagnosis, and reduction 
in rising healthcare costs[59]. Infectious diseases such as malaria, and dengue can be easily 
diagnosed with a simple blood test for a timely treatment. Routine monitoring of blood 
sugar levels is performed by diabetics. Blood pressure and cholesterol levels are 
periodically checked by people with cardiovascular diseases. 
 
 
2.2.1 Sources for biomarkers 
Biomarkers have been detected in various body fluids. Most commonly used body fluids 
for biomarker detection are blood[60], urine[61], saliva[62], tears[63], and sweat[64].  
However, the gold standard for most diagnostic tests is blood because it is well studied and 
is systemic. Blood may be collected via venipuncture, or finger stick. Venipuncture is the 
extraction of blood from the vein by using a needle and a syringe. Finger stick, also known 
as capillary puncture, involves blood collection by puncturing the fingers, ear lobes, or the 
big toe side of the heel (in infants) with the use of a lancet. 
Finger sticks are routinely done by patients to collect capillary blood. Finger sticks are 
commonly done at home for blood glucose monitoring, pro-thrombin measurements. 
However, blood volume collected by finger sticks are variable and may be erroneous due 
to contaminants from skin surface[65].  
Venipuncture allows for multiple blood collections and collection of larger blood volumes. 
The samples can be stored in vacutainer containers for future testing too. It provides more 
reliable results because the specimens are collected directly from the systemic circulation. 
However, the main disadvantage of venipuncture is the need for a skilled phlebotomist to 
perform the blood draw. Another disadvantage is the difficulty to perform it in infants, 
obese people or burn victims.  
Other body fluids such as tears, sweat, urine and saliva are easy to access. Most commonly 
used urine based test is for detection of ovulation, or pregnancy [66]. However, 




Saliva can be used for detection of drug concentrations and diseases pertaining to the 
gastrointestinal track [69]. Saliva has also been used for diagnosis of glucocorticoid related 
diseases[70]. Antibodies present in saliva could be used for diagnosis of many infections 
such as hepatitis A and B [71]. However, the accuracy of these assays are affected by 
presence of food substances in the mouth. 
There has been a significant interest in sweat analysis due to its potential for detecting 
sodium content which can provide valuable information about an individual's physical and 
mental wellbeing[72]. However, currently available methods for sweat analysis are not 
optimized for in home usage. 
Tear fluid also has the potential to be used for diagnosis. Proteomic pattern of tear fluid 
has been shown to be useful for breast cancer detection[73]. However, it is challenging to 
collect tear fluid samples frequently. 
2.2.2 Interstitial fluid (ISF) 
The human body fluids can be conceptually divided into two main fluid compartments: 
intracellular and extracellular compartments.  The intracellular compartment comprises of 
fluid enclosed in the cells by their plasma membranes. Cytosol or cytoplasm is the principal 
component of intercellular compartment. The extracellular fluid compartments mainly 
consists of blood (also called plasma), and ISF. A small portion of the extracellular fluid 
comprises of cerebrospinal fluid (fluid in brain and spinal cord), synovial fluid (fluid in 
joints), pleural fluid (fluid in the pleural cavities), pericardial fluid (fluid in cardiac sac), 
 
 
peritoneal fluid (fluid in the peritoneal cavity) and the eye’s aqueous and vitreous humor
.            
Figure 2-2: Pie chart showing the percentages of intracellular and extracellular 
fluids[74,75] 
 
Also known as tissue fluid, ISF is the fluid found between the cell spaces. It leaks out of 
the blood capillaries due to transcapillary exchange during blood flow from arterioles and 
venules. The main function of ISF is to provide oxygen and essential nutrients to the cells. 
The ISF is constantly reabsorbed into the systemic circulation or drains into the lymph 
vessels.  ISF forms around 20-25% of body weight [74]. 
There are several mechanisms involved in transcapillary exchange of fluid. The most 
important are bulk flow and diffusion. The net driving force is determined by the 
hydrostatic pressure, oncotic pressure and the permeability of the capillary wall separating 












There are two opposing hydrostatic pressures: capillary hydrostatic pressure (Pc) and tissue 
interstitial hydrostatic pressure (Pi). The net hydrostatic pressure gradient (PC - Pi) across 
the capillary is positive, because Pc is normally higher than Pi. Hence, the net hydrostatic 
pressure gradient drives the fluid out of the capillaries.  
The two opposing oncotic pressures are: capillary oncotic pressure (c) and tissue oncotic 
pressure(i). The capillary oncotic pressure is dependent on plasma proteins which are 
impermeable through the capillary. The net oncotic pressure gradient (c - i) would 
reabsorb the fluid back into the capillary. The net oncotic pressure is also dependent on the 
permeability of the capillary walls. Hence, the net driving force (NDF) for fluid movement 
is dependent on individual pressure gradients.  
 Equation 1  
 NDF = (PC - Pi) - (c - i)        (1) 
where  is the reflectance coefficient, a measure of the permeability of the capillaries to 
proteins causing oncotic pressure. NDF > 0 results in filtration of fluid from the capillaries 
to the interstitium while NDF < 0 results in reabsorption. 
The capillary walls allow most hydrophilic small molecules to freely equilibrate between 
the plasma and ISF. Hence, the concentration of sodium, chloride and glucose should be 
similar between ISF and plasma. ISF contains important amino acids, fatty acids, 
hormones, salts, coenzymes etc.[77] from cells and cell debris. 
Many previous studies have shown the potential to use ISF for diagnosis of biomarkers of 
interest. ISF contains many unique biomarkers and certain biomarkers are elevated in ISF 
 
 
compared to plasma[78]. Since it contains cellular and systemic biomarkers, ISF can be a 
valuable body fluid that can be used to detect systemic and local environmental changes. 
Unlike blood, ISF does not clot. This provides ISF the unique advantage for continuous 
monitoring such as analysis of biomarkers for exhaustion prediction[79]. This is the reason 
for the recently developed commercial glucose monitoring devices by companies such as 
Dexcom[80] and Medtronic[81]. 
2.2.3 Methods for ISF collection 
Various methods have been developed to collect ISF from skin. Some of the methods are 
suction blister, microdialysis/microperfusion, reverse iontophoresis, use of ultrasound 
and microneedles. 
2.2.3.1 Suction blister method 
Suction blister method, initially developed in 1968[82], is the most widely used method 
for ISF collection.  As the name implies, this method involves artificially inducing 
blisters by usage of negative pressure for up to 2 hours at an elevated temperature of up 
to 40°C.  The procedure involves slow detachment of the epidermis from the underlying 
dermis which induces the blister to be filled with ISF. The ISF can then be collected with 
a conventional needle and syringe. This technique has been used to assess wound 
healing[83], and effectiveness of psoriasis[84] and vitiligo treatment[85]. However, the 
disadvantages of this method include the need for specialized equipment and expertise, 
long procedure times (up to 2 hours), and increased risk of infections. The wound could 
take 7-10 days to heal. Some subjects develop hyperpigmentation at the wound site which 
 
 
could last for several months. This is still the only technique available to sample large 
volumes of ISF. 
2.2.3.2 Suction effusion 
This method involves using an adhesive tape to remove the SC followed by application of 
a suction device. Kayashima et al. collected 35ul/hr of ISF for 3 hours by applying 
400mm Hg of negative pressure after tape stripping 7.1cm2 of skin area of rabbit[86].  
However, concerns regarding the invasive nature of tape stripping have limited the utility 
of this method. 
2.2.3.3 Wick sampling 
This method was first performed by Aukland et al. in 1973[87]. It involves implanting 
nylon wick into the subcutaneous tissue of rats to collect ISF. The wicks imbibe the ISF 
which is later extracted by centrifugation.  Some of the disadvantages of this method are 
small sample volumes and its invasive nature. However, wick sampling has been used by 
several investigators both in animals[88] and humans[89].  
2.2.3.4 In-vivo ultrafiltration 
This method involves insertion of a small probe with semipermeable membrane into the 
tissue. Application of negative pressure induces the convective flow of ISF. The 
semipermeable membrane has a molecular cutoff of 20kDa to 50kDa, thereby excluding 
protein and cell fragments. Ultrafiltration probes have only been used in animal studies 
due to the invasive nature of the procedure and potential risk of infection. However, this 
method does allow sampling of microliter quantities of ultrafiltrate from skin, or even 
bone interstitium[90].  
 
 
2.2.3.5 Microdialysis and microperfusion 
Microdialysis was first used by Ungerstedt and Pycock in 1974 for measurement of 
neurotransmitter concentrations in rat brain[91]. This technique can be used for 
continuous sampling of unbound analyte concentrations in extracellular fluid from any 
tissue.  
The microdialysis system involves a dialysate pump, a microdialysis probe and a 
collection system for the microdialysate. The probe with a semipermeable hollow dialysis 
membrane is implanted into the skin. The perfusate is flown through the probe at a 
predetermined flow rate by means of a volumetric micropump. The solutes present in ISF 
slowly diffuse into the perfusate due to concentration gradient. The perfusate containing 
components of ISF is finally collected. Microdialysis is a useful method for measuring 
concentrations of low molecular weight analytes. This method has been used for 
measurement of glucose[92] and other biomarkers[93,94]i. However it is not suitable for 
measuring protein concentrations due to the molecular weight cut off of the 
semipermeable membrane. Also, frequent calibration is required to ensure sensitivity and 
precision in concentration measurements. 
Open flow microperfusion method involves implantation of a stainless steel mesh into the 
skin. The perfusate flows through the mesh and collects components from ISF via 
diffusion. Since, no dialysis or filtration occurs, the perfusate collects proteins too. This 
method has been used for monitoring drug concentrations in the skin[95]. The 
disadvantage of this method is the small amount of ISF collected over time, which results 
in poor time resolution, and the invasive nature of the procedure. 
2.2.3.6 Reverse Iontophoresis 
 
 
This technique was first used by Benjamin et al. to extract subcorneal potassium and 
sodium[96]. In this method, a small electric current (usually 0.2-0.8mA) is applied across 
the skin. Since skin is negatively charged, it allows for preferential electromigration of 
small cationic substances towards the cathode. The movement of these ions induces a 
convective flow of ISF that contains uncharged water-soluble substances such as glucose 
and urea by electrosmosis towards the skin surface. The non-invasive nature of this 
method has resulted in development of point of care diagnostic devices. 
Glucowatch is one such device that measures concentration of glucose in skin by reverse 
iontophoresis[97]. However, some of the limitations of this method include the need for 
frequent calibration to maintain accuracy[98] and the possibility for skin irritation due to 
continuous use and prolonged application of electric current across skin. 
2.2.3.7 Low frequency ultrasound 
This method can be used to sample dermal ISF non-invasively. This method uses low 
frequency ultrasound (20 kHz and 7W/cm2 intensity for < 1 min) to disrupt the SC and 
enhance the permeability of ISF onto the skin surface[99]. 
2.2.4 Microneedles for sampling ISF 
There has been a rapid progress in microfabrication techniques. MNs have not only been 
used to deliver vaccines, drugs but have also been investigated as a diagnostic tool to 
extract analytes from the skin for sensing[100].  MNs can enable minimally invasive 
sampling of dermal ISF. They are portable, hence can be easily adapted to point of care 
devices. Unlike the transdermal patches, MNs penetrate the SC and directly access the 
ISF.   
 
 
There could be two approaches for using MNs in diagnostics. MNs could be used to form 
micropores on the skin surface to provide pathway for the flow of ISF onto the surface. 
The ISF can then be collected and analyzed for the biomarker of interest. 
Another approach could be to have a MN device with a built in sensor for collection and 
detection of a specific biomarker. Research has been focused on both of these 
approaches.  
Kobayashi et al. developed a hollow MN system inspired by blood extraction action of a 
mosquito. The MN system was made with a phase transition gel as actuator[101]. The gel 
characteristics were modified for continuous glucose monitoring[102].  
Mukerjee et al. developed a hollow silicon MN patch using deep reactive ion 
etching[103]. Upon insertion in the skin, the hollow MNs drew ISF via capillary forces 
and collected into a reservoir. The device was tested in humans for qualitative glucose 
detection onto a colorimetric paper after 15-20 min extraction [104]. In one approach, up 
to a few microliters of ISF were extracted under suction from skin pretreated with MNs; 
measured glucose concentrations in the extracted ISF showed excellent correlation with 
corresponding blood glucose levels in rats and human subjects [105]. 
Miller et al. developed MNs with integrated carbon fibers in the bore for detection of 
small analytes such as ascorbic acid [106].They also performed in-vivo human studies 
and successfully detected hydrogen peroxide and lactate concentrations [107]. They 
further developed a multiplexed MN sensor by enzyme functionalizing the carbon paste 
and demonstrated the utility of this MN sensor to simultaneously detect pH, lactate and 
glucose [108]. Miller et al. also developed a hollow MN device with built in solid state 
ion selective electrodes for sensitive detection of potassium ion concentrations [109]. 
 
 
Wang et al. used solid glass MNs to form micropores in the skin. A negative pressure 
(200-500 mmHg) was then applied for 2-10 min. ISF (1-10 µl) was then collected from 
skin surface of mice and humans. Glucose concentrations in ISF and blood were found to 
be well correlated and a lag time of change in glucose concentration in ISF was found to 
be ~10 min [110].  
Zimmerman et al.  developed a MN patch with built in glucose sensor. The MNs were 
250 µm long and used capillary action to collect ISF. In-vitro testing showed linear 
response to glucose concentration, however, the device response was variable in vivo due 
to variation in flowrates [111]. 
Other researchers developed a similar device based on hollow MN device with built in 
glucose oxidase based sensor [112]. There is a growing interest in the area of continuous 
glucose monitoring with new innovations such as a self-powered biofuel cell based 
glucose sensor[72] and a single MN patch system for glucose sensing and insulin 
delivery [113]. 
Corrie et al. developed a MN array coated with a capture protein for in-situ detection of 
influenza specific antibodies in mouse plasma and ISF [114]. Similarly Muller et al. 
coated microneedles with dengue virus NS1 and IgG specific proteins and demonstrated 
that the NS1 levels in ISF and blood correlated well [115]. 
Sato et al. developed a microneedle system for measurement of interstitial glucose. They 
used solid MNs to make micro pores on the skin, and then placed a hydrogel patch with 
an osmolyte on the pretreated site for ISF extraction. The study compared blood glucose 
levels on diabetic and non-diabetic patients. The blood and ISF glucose levels were well 
correlated and the lag time was found to be ~10 min [116].  Donnelly et al. developed 
 
 
swellable microneedles made of copolymer of methyl vinyl ether and maleic acid. The 
MNs remained in dry state initially but were swollen by ISF upon insertion into skin 
[117]. Caffarel-Salavdor et al. inserted these MN patches in human subjects and 
correlated caffeine and glucose concentrations in ISF and blood. The caffeine and 
glucose concentrations were 2-3 orders of magnitude lower in the ISF and the lag time 
was as high as 3 hours. This implies that the ISF extraction rate was very low [118]. 
Romanyuk et al. developed crosslinked hydrogel microneedles composed of poly (methyl 
vinyl ether-alt-maleic acid) and poly (ethylene glycol). They demonstrated that upon skin 
insertion, the MN patches swelled with ISF which was later collected by centrifugation 
[119]. Chang et al. showed that their swellable microneedles could collect up to 3ul of 
ISF in 30 min. They demonstrated good correlation between glucose and cholesterol 
levels in ISF and blood [120]. More recently, Samant et al. used MN patch to form 
micropores on skin and collected 1-10 µl of ISF by applying vacuum. They demonstrated 
that the rate-limiting step for ISF sampling is often transport through the skin to the site 
of MN puncture, and forces that generate convective flow in the skin can significantly 
facilitate ISF collection[121]. 
2.2.5 Motivation for research on ISF collection using microneedles 
Most of research previously conducted for ISF collection involved usage of MN devices 
which collect submicroliters of fluids, and the ISF collection process is time consuming. 
ISF remains an unexplored body fluid because of a general need for simple methods to 
sample this fluid reliably and quickly. 
 
 
The goal of this study is to develop a simple, easy to use MN device for collection of 
microliters of ISF within minutes. The development of a reliable and simple MN system 
could enable exploratory research on biomarkers in ISF.  
Development of such a MN device could have a large impact on clinical medical 
diagnostics. Having a portable MN device for quick and easy detection and monitoring of 
chronic disease such as diabetes, cardiovascular disease could be beneficial. Such devices 
could also be used by elite athletes or people with high stress jobs for detection of 
biomarkers such as lactate, creatinine, and uric acid.  A MN device made with inexpensive 
and easily available materials and that requires minimal training to use, could be well suited 
for use as diagnostic or monitoring systems, including in developing countries. 
Other potential uses include detection of drugs and other biomarkers of interest in ISF. For 
example, Vancomycin is an antibiotic which has a very narrow therapeutic index and 
warrants a therapeutic drug monitoring (TDM) to ensure efficacy and minimize toxicity 
during patient care [122]. Kiang et al. used ultrafiltration probe to sample ISF and 
demonstrated similar vancomycin concentration-time profiles in ISF and blood, in rabbits 
[123]. Other researchers have shown promising results with similar AUC between serum 
and ISF samples for drugs such as scopolamine, theophylline, methotrexate, 
carbamazepine and phenobarbital in ISF [124-126]. However, the methods employed for 
ISF collection are invasive and may not be translated into humans. Hence, there is a need 




CHAPTER 3. SPECIFIC AIMS AND HYPOTHESES 
Aim 1a: Formulate thermostable MN patch for polio vaccination  
Hypothesis: Fabrication of MN patch by optimization of formulation i.e. excipients and 
biopolymers and processing conditions, i.e. drying time stabilizes polio vaccine during 
extended storage at elevated temperature. 
Expected outcomes: Characterization of how formulation and process parameters affect 
IPV stability and design of optimized MN patch which is thermostable. 
Aim 1b: Characterize relationships between changes in MN patch material properties 
and IPV stability 
Hypothesis: Characterization of the optimized MN patch will help understand excipient-
IPV interactions. 
Expected outcomes: Identification of possible correlations between MN patch properties 
and IPV by DSC, TGA, and other techniques. 
 
Aim 2: Develop an easy to use paper based MN patch for ISF collection 
Hypothesis: Optimization of MN patch parameters will result in an MN patch for easy ISF 
sampling.  
Expected outcomes: Identification of possible MN parameters which influence the ISF 
collection and design of an optimized MN patch which can easily collect 2- 4 µl of ISF 
within a minute. 
 
Aim 3: Demonstrate the utility of the optimized MN patch for detection of biomarkers 
of interest in ISF 
Hypothesis: The optimized MN patch will be able to collect sufficient quantities of ISF for 
quantitative detection of biomarkers of interest in ISF.  
Expected outcomes: Extraction and quantification of biomarkers of interest in ISF and 





CHAPTER 4. DEVELOPMENT OF A THERMOSTABLE MICRONEEDLE 
PATCH FOR POLIO VACCINATION 
4.1 Introduction 
Poliomyelitis is a highly infectious disease which mainly affects children. The disease 
can be caused by any of the three serotypes of IPV (type 1, type 2 or type 3) and can be 
prevented by immunization[127] Thanks to the Global Polio Eradication Initiative 
(GPEI), the number of polio cases has dropped from 350,000 in 1988 to only 22 reported 
cases in 2017ii. IPV type 1 is the only serotype that is currently endemic to three 
countries (Afghanistan, Nigeria, and Pakistan) and wild-type IPV type 2 has been 
eradicated[128]. However, WHO predicts that failure to eradicate this disease can reverse 
these advances and cause as many as 200,000 new cases every year in 10 years[15].  
 The progress made so far is predominantly due to mass vaccination using the oral 
polio vaccine (OPV) which is a live-attenuated virus given my mouth[129]. OPV offers 
advantages such as low cost, ease of administration only requiring oral delivery of two 
drops of vaccine, no sharps and generation of mucosal immunity. However, a major 
concern with OPV is the possibility of genetic reversion to a virulent form that can cause 
vaccine-associated paralytic polio (VAPP)[19] and can be transmitted to others. A safer 
alternative is inactivated polio vaccine (IPV), which does not carry the risk of paralysis or 
transmission, but is administered as an intramuscular (IM) injection[130]. 
 To eliminate the risks of VAPP, OPV was replaced by IPV in United States and 
United Kingdom in 2000 and 2004, respectively[21], and plans to discontinue use of 
OPV worldwide by 2019 are underway[131]. However, the biggest drawbacks of 
 
 
switching to IPV are the need for trained medical professionals administer IM injections, 
generation of sharps waste, need for cold chain storage, high cost of the vaccine, and 
need for multiple doses for a protective immune response[16,23,28].  
 In this study, we propose the use of a dissolving microneedle (MN) patch for IPV 
vaccination. When a MN patch is applied to the skin, micron-scale, solid needles made of 
safe, water-soluble excipients that encapsulate vaccine penetrate the outer barrier layer of 
the skin, where they dissolve and release their vaccine payload[29]. MN patches can be 
self-administered painlessly[41,132,133] generating no sharps as waste and have been 
used previously for various vaccinations[134] ,including IPV[135] and a recent clinical 
trial on influenza [43]. Encapsulation of vaccines in appropriately formulated MN 
patches has been shown to increase vaccine thermostability [136].  It was therefore our 
objective to formulate a MN patch for IPV vaccination that can provide thermostability 
that reduces reliance on cold-chain storage, eliminate the need for administration by 
trained health care professionals and avoid the safety risks and disposal costs of sharps 
waste. This approach could facilitate mass vaccination campaigns, especially in 
developing countries, which are needed to achieve polio eradication [137]. 
 
4.2 Materials and methods 
4.2.1 Concentration of inactivated polio vaccine 
Monovalent, bulk IPV (Mahoney strain of type 1, Middle East Forces (MEF) of type 2 and 
Saukett of type 3) was kindly provided by Bilthoven Biologicals (Bilthoven, Netherlands). 
The initial antigen concentrations were 1675, 963 and 950 D-antigen units (DU)/ml for 
 
 
IPV types 1, 2 and 3, respectively. The bulk IPV was concentrated using Amicon Ultra 
centrifuge spin filters with 100 kDa MW cutoff (EMD Millipore, Billerica, MA)  either 
~10-fold by volume to a final antigen concentration of 1.7 x 104, 9.6 x 103 and 9.5 x 103 
DU/ml for IPV types 1, 2 and 3, respectively, or ~47- fold by volume to a final antigen 
concentration of 7.9x 104, 4.8 x 104 and 4.5 x 104 DU/ml for IPV types 1, 2 and 3, 
respectively. All D-antigen values were determined by ELISA, as described below. 
4.2.2  Vaccine stability screening 
To increase throughput of formulation screening, candidate vaccine-excipient formulations 
were dried on polydimethylsiloxane (PDMS) chips, which are representative of the surface 
of a MN patch mold. PDMS chips were prepared by curing a thin film of Sylgard 184 (Dow 
Corning, Midland, MI) and preparing 6 mm diameter circular discs using a hammer punch.  
IPV was concentrated 10-fold by volume and mixed with selected excipients. A 10 µl drop 
of formulated vaccine solution was placed on each chip and allowed to dry at 5 °C in a 
desiccator filled with desiccant (Drierite, W A Hammond Drierite, Xenia, OH) overnight. 
After reconstituting the dried IPV in 999 µl  media M199, the D-antigen content of the IPV 
was determined by ELISA, as described below. All excipients were purchased from Sigma 
Aldrich (St. Louis, MO). 
 
4.2.3 Microneedle patch fabrication 
PDMS molds consisting of a 10 x 10 array of cavities that form the MNs were fabricated 
as described previously[138]. The antigen casting solution was prepared by mixing 47-fold 
 
 
concentrated vaccine with a solution consisting of a 10% w/v maltodextrin and D-sorbitol 
in 0.35 mM histidine buffer at pH 6.3. Fifty microliters of the antigen solution was cast 
onto a MN mold, which was then centrifuged for 1 h at 5 °C to fill the mold cavities with 
solution and partially dry the solution in the mold, following a procedure previously 
described[139].   
 The polymer matrix solution used to form the MN patch backing consisted of 35% 
w/v fish gelatin and 10% w/v D-sorbitol in 0.15 mM histidine buffer. The solution was 
mixed for 1 h at 35 °C until completely dissolved. Two hundred microliters of polymer 
matrix solution was cast onto a mold pre-filled with partially dried antigen solution. The 
mold was then placed under vacuum for 2 h at room temperature (20 – 25 °C) and stored 
in a desiccator at room temperature for 2 days before demolding. Demolded patches were 
packaged with desiccant in aluminum pouches to maintain 0% RH (relative humidity) and 
stored at a given temperature (i.e. 5, 25 or 40 °C) in stability chambers. For experiments 
involving storage at ~50% RH, patches were stored in a desiccator containing a saturated 
solution of magnesium nitrate in distilled water[140].  
 
4.2.4  Microneedle composition  
The composition of MNs (i.e., just the MNs without the patch backing) was determined by 
preparing placebo patches (i.e., with no IPV, but otherwise fabricated in the same way) and 
carefully cutting off the MNs. The MNs were reconstituted in water and the protein content 
was determined using micro BCA protein assay kit (Thermo Fisher Scientific, Waltham, 
MA), which was interpreted to be roughly equal to the gelatin content, since the only 
 
 
protein in a placebo patch should be gelatin from the polymer matrix solution used during 
the second cast which could migrate into the MN during the fabrication process. In this 
way, the composition of the MNs was estimated to be fish gelatin, D-sorbitol and 
maltodextrin in a mass ratio of 55: 38: 7. This formulation was used when studying IPV 
stability on chips that simulate MN composition. The chips were stored at a given 
temperature ( i.e. 5, 25 or 40 °C)  for specified times in stability chambers. 
 
4.2.5 Lyophilization 
To study the effect of lyophilization on IPV stability, demolded MN patches and dried IPV-
excipient chips were subjected to lyophilization (VirTis AdVantage 2.0 BenchTop 
lyophilizer, SP Industries, Warminster, PA). The lyophilization process involved a primary 
drying at -45 °C (10 mTorr) for 3 h followed by a secondary drying at 25 °C (10 mTorr) 
for 24 h. The samples were removed from the lyophilizer and stored in a desiccator until 
tested. 
 
4.2.6 Microneedle patch characterization 
MN patches were imaged using brightfield microscopy (Hirox KH-8700, Tokyo, Japan). 
To assess MN insertion into skin, patches were pressed by thumb onto stretched porcine 
cadaver skin. The MNs were left in the skin for 15 min, and then removed. The skin was 
stained for 5 min, with gentian violet (2% solution, Humco, Texarkana, TX), which was 
 
 
then wiped off to show preferentially stained sites of MN penetration into skin[4]. The 
removed MN patches were imaged to determine extent of MN dissolution. 
 
4.2.7 ELISA assay measurements 
The D-antigen content of IPV from chips and MN patches was determined by antigen-
capture sandwich ELISA, as previously described[42]. Polio-specific monoclonal 
antibodies were used for both capture and detection. The capture antibody solutions were 
prepared by adding type 1 (HYB295-15-02), type 2 (HYB294-06-02) or type 3 (HYB300-
05-02) (Thermo Fisher Scientific) specific antibodies to 0.05 M carbonate-bicarbonate 
buffer, pH 9.6. Type 1 and type 3 antibodies were diluted at 1:1000 and type 2 was diluted 
in 1:500.  
 
4.2.8 Thermogravimetric analysis 
Thermogravimetric analysis (TGA, Q50, TA Instruments, New Castle, DE) was used to 
determine the residual moisture content of the MN patches. Samples obtained from MN 
patch (each weighing 15–20 mg) were heated at 10 °C/min from room temperature to 
110 °C and then maintained isothermally for 10 min. The residual moisture content (%) 
was determined by the stable weight loss (%) at 110 °C using TA Instruments Universal 




4.2.9 Differential scanning calorimetry 
Differential scanning calorimetry (DSC, Q200, TA Instruments) was used to measure the 
glass transition temperature of the samples. Samples obtained from MN chips (each 
weighing 10–15 mg) were placed in hermetically sealed aluminum pans (TA Instruments, 
cooled from room temperature to 0 °C at a rate of 10 °C/min and subsequently heated to 
200 °C at a heating rate of 10 °C/min. The sample chamber was purged with dry nitrogen 
at 50 ml/min. Empty pans were used as a reference control. The onset temperature of the 
discontinuities in the heat flow versus temperature curve was taken as the glass transition 
point, which was determined using TA Instruments Universal Analysis 2000 software.  
 
4.2.10 X-ray diffraction 
X-ray diffraction (XRD, X’pert Pro Multi-Purpose Diffractometer, PANalytical, West-
borough, MA) analysis was used to study structural changes of MN chips stored at 
specified temperatures over time. The measurements were made in the θ - 2θ mode on the 
MN chip samples using a bracket sample holder with a Cu Kα radiation source (Cu Kα = 
1.54059 Å) at room temperature. Data were collected between 2θ values of 5° and 50° 
using a step size of 0.013° and an acquisition time of 30 s per step. Samples were measured 
at 45 kV and 40 mA. X-ray diffraction patterns were analyzed using Jade 8 software (MDI 
Materials Data, Livermore, CA) and shown after background correction. Diffraction peaks 




4.2.11 Fourier-transform infrared spectroscopy 
Fourier-transform infrared spectrometry (FTIR, Nicolet iS 50 FT-IR, Thermo Fisher 
Scientific, Waltham, MA) was used to study structural changes of MN chips stored at 
specified temperatures over time. The FTIR spectra of the samples were recorded at room 
temperature from 4000 to 600 cm-1 and shown after background correction. 
 
4.2.12 Statistics and Design of Experiments 
The Design of Experiments model for excipient screening was developed using MiniTab 
software version 18 (MiniTab, State College, PA). Statistics were calculated using either 
MiniTab or Excel (Microsoft, Redmond, WA). All listed averages represent the arithmetic 
mean of the samples. Comparison between three or more samples was performed by one-
way ANOVA or the data were fit to a general linear model. Comparisons between 
individual samples were done using an unpaired t-test. Probability (p) values of <0.05 were 
considered to be significant. 
4.3 Results and discussion 
4.3.1 Excipient screening for IPV stabilization  
To identify formulations that stabilize IPV during MN patch fabrication, we studied 
excipients including maltodextrin, which was previously shown to stabilize IPV[42], and 
D-sorbitol, sucrose and trehalose, which are widely used to stabilize proteins during drying 
or lyophilization[55,141]. Using a Design of Experiments model [see Table A-1 in 
 
 
Appendix A], we studied the effect of individual excipients as well as combinations of up 
to four excipients, because multiple stabilizers have often been shown to provide better 
stability than individual excipients[142].   
 Trivalent concentrated IPV was formulated with combinations of different 
excipients in histidine buffer and dried on PDMS chips at 5 °C overnight. The samples 
were then lyophilized and stored at 25 °C with desiccant for 1 week. Each sample was 
reconstituted and assayed for D-antigen binding activity by ELISA. 
 In general, varying formulation of IPV type 3 (Figure 4-1) and types 1 and 2 (Figure 
A-1) had little effect of vaccine stability (two-way ANOVA, p > 0.05), as determined by 
D-antigen content measured by ELISA, probably because we selected excipients already 
shown or expected to stability IPV. After air drying, IPV typically lost very little activity 
(two-way ANOVA, p > 0.05), but then lost significant activity after subsequent 
lyophilization (two-way ANOVA, p < 0.004). Sometimes there were additional losses in 
IPV activity after storage at 25 °C, 0% RH for 1 week, but in most cases post-lyophilization 
and post-storage activity values were similar (two-way ANOVA, p > 0.05). In general, IPV 
type 2 was most stable, followed by IPV type 1 and IPV type 3 (three-way ANOVA, p > 





Figure 4-1: Effect of stabilizing excipients on IPV type 3 activity before drying, after 
air drying, after subsequent lyophilization and after storage. Vaccine was 
formulated with combinations of different excipients (each present at a 
concentration of 5% w/v) in 0.1 M histidine buffer at pH 6.5 (see Table S1 in SI for 
key to excipient formulations). In each set of bars, the first bar shows activity of 
liquid IPV formulated with excipients before drying. The second bar shows IPV 
activity after air drying at 5°C with desiccant overnight after casting onto PDMS 
chips. The third bar shows IPV activity after lyophilization. The fourth bar shows 
IPV activity after storage lyophilized vaccine at 25 °C with desiccant for 1 week. 
The unformulated vaccine control data is shown as D6 bars on the far left. All IPV 
activity (determined by ELISA) is shown as percentage of the starting stock 
solutions of concentrated vaccine. Asterisk (*) indicates excipient formulation that 
maintained >80% activity after drying and storage. Data represent mean ± SEM 
(standard error of the mean) of n= 3 replicates. Companion data on IPV types 1 and 
2 are show in Figure A-1 in Appendix A. 
  
It is notable that all three serotypes of unformulated IPV lost ~75 – 90% activity after air 
drying and lost ~90 - 100% activity after lyophilization (and storage). In contrast, none of 
the formulated vaccine samples lost more than 60% activity after drying, lyophilization 
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maltodextrin and D-sorbitol (50:50 mass ratio), which maintained at least 80% activity 
after drying, lyophilization and storage. 
 
4.3.2 Buffer and pH screening 
To assess the effect of buffer and pH, IPV activity was determined after air drying, 
lyophilization and storage at 40 °C for 3 days and 7 days using three different buffers and 
three pH values. Overall, buffer had a greater effect on activity loss (general linear model, 
p < 0.05) than pH (general linear model, p < 0.12), over the range of conditions studied 
(Figure 4-2 and Figure A-2 in Appendix A). Histidine buffer maintained activity of type 3 
IPV (general linear model, p > 0.80) while potassium hydrogen pthalate (KHP) buffer had 
the most adverse effect (general linear model, p < 0.03) (Figure 4-2); similar findings were 
observed in IPV types 1 and 2 (Figure A-2 in Appendix A), although the differences in 
effects of pH and buffer were less dramatic compared to IPV type 3. Histidine buffer at pH 
6 was selected as the best buffer to stabilize all three serotypes. Subsequent MN patch 
optimization experiments led to 0.35 mM histidine buffer for the first cast formulation and 
0.15 mM histidine buffer for the second cast formulation. These buffer concentrations in 
combination with the other excipients (that can also influenza pH) were selected to yield a 
final pH of 6.3.  
 
 
   
Figure 4-2: Effect of formulation buffer and pH on IPV type 3 activity after drying 
on PDMS chips followed by lyophilization and storage. IPV was formulated with 
5% w/v maltodextrin and 5% w/v D-sorbitol in 0.1 M buffer with pH adjusted using 
1 N HCl or 1 N NaOH. Storage was carried out at 40 °C for 3 or 7 days with 
desiccant. KHP: Potassium hydrogen pthalate, M199: Medium 199. In each set of 
bars, IPV activity is shown in the first bar after air drying at 5°C overnight and 
lyophilization, in the second bar after storage in a desiccator at 40 °C for 3 days and 
in the last bar after storage at 40 °C in a desiccator for 1 week. Stability of 
unformulated IPV (i.e., without maltodextrin or D-sortibol) in M199 media is shown 
in the bars on the far right.  Asterisk (*) represents buffer which had the most 
adverse effect on IPV stability (general linear model, p < 0.03). All IPV activity is 
shown as percentage of IPV activity vaccine casting solution. Data represent mean ± 
SEM of n= 3 replicates. Companion data on IPV types 1 and 2 are show in Figure 
A-2 in Appendix A.  
 
4.3.3 Optimization of polio MN patches 
Initial formulation studies above were performed by casting onto flat PDMS chips to 
facilitate higher throughput. We next assessed formulation optimization in the context of 
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4.3.3.1 Optimization of 1st cast formulation 
The first solution cast onto the MN mold contained IPV formulated with maltodextrin and 
D-sorbitol in different ratios (IPV type 3 in Figure 4-4; IPV types 1 and type 2 in Figure 
A-3 in Appendix A). There was no significant effect of maltodextrin:D-sorbitol ratio on 
activity of IPV types 1, 2 or 3 (2-way ANOVA, p > 0.8). A maltodextrin:D-sorbitol ratio 
of 20:80 (on a dry basis, when cast as 10% w/v solids in solution) was selected as the best 
formulation because this ratio consistently enabled fabrication of MN patches with sharp 
microneedle tips.  
 
Figure 4-3: Effect of 1st cast excipient ratio (maltodextrin:D-sorbitol) on IPV type 3 
activity after fabricating MN patches, air drying, lyophilization and storage with 
desiccant at 40 °C for 2 days. Trivalent IPV was formulated with stabilizing 
excipients at a total concentration of 10% w/v in the vaccine casting solution. The 
maltodextrin: D-sorbitol mass ratios were 80:20 (MS80), 50:50 (MS50) and 20:80 
(MS20). The 2nd cast polymer matrix solution consisted of excipients at a total 
concentration of 45% w/v fish gelatin and D-sorbitol (at a mass ratio of 78:22) in 
0.15 mM histidine buffer at pH 6.3. All IPV activity is expressed as a percentage of 
IPV activity in the vaccine casting solution. In each set of bars, the first bar shows 
IPV activity in MN patch after air drying at 5°C in a desiccator for 2 days; the 
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IPV activity after storage at 40 °C for 1 week with desiccant. There was no 
significant difference between the different ratios of maltodextrin-to-D-sorbitol (2-
way ANOVA, p > 0.8). Data represent mean ± SEM of n= 3 replicates. Companion 
data on IPV types 1 and 2 are show in Figure A-3 in Appendix A.  
 
4.3.3.2 Optimization of 2nd cast formulation 
MN patch preparation process involves the addition of a second cast solution which not 
only forms the MN patch backing but also provides additional mechanical strength to the 
MNs. To determine the effect of ratio of 2nd cast excipients, MN patches were prepared 
with a 1st cast consisting of trivalent IPV formulated with maltodextrin and D-sorbitol 
(20:80) and a second cast solution consisting of varying ratios of fish gelatin to D-sorbitol 
in 0.15 mM histidine buffer (IPV type 3 in Figure 4-4; IPV types 1 and type 2 in Figure 
A-4 in Appendix A).  
 No significance differences in IPV type 1 and type 2 activities were observed 
between GS78 and GS55 formulations (ANOVA, p > 0.05), but GS78 was better in 
stabilizing IPV type 3 (ANOVA, p < 0.05).  However, MN patches prepared with GS55 
formulation were not mechanically robust enough to penetrate the skin. GS88 had adverse 
effects on all three IPV serotypes (ANOVA, p< 0.05), especially after extended storage at 
40 °C. 
 Hence, a fish gelatin:D-sorbitol ratio of 77:22 (on a dry basis, when cast as 45% 
w/v solids in solution) was selected as the final 2nd cast formulation because it resulted in 
the best stabilization of all three IPVs types and produced MN patches with strong 




Figure 4-4: Effect of 2nd  cast excipient ratio (fish gelatin-to-D-sorbitol) on IPV type 
3 activity after fabricating MN patches, air drying, lyophilization and storing with 
desiccant at 40 °C for 7 days. Trivalent IPV was formulated with stabilizing 
excipients at a total concentration of 10% w/v in the vaccine casting solution. The 
maltodextrin: D-sorbitol mass ratios were Trivalent IPV was formulated with 
stabilizing excipients at a total concentration of 10% w/v in the vaccine casting 
solution. The maltodextrin: D-sorbitol ratio was 20:80 in 0.35 mM histidine buffer. 
The 2nd casting solution containined 45% w/v with varying mass ratios of fish 
gelatin-to-D-sorbitol in 0.15 mM histidine buffer. The mass ratios used were GS88 
(fish gelatin:D-sorbitol = 88:11), GS78 (fish gelatin:D-sorbitol = 78:22) and GS55 
(fish gelatin:D-sorbitol = 55:45). All IPV activity is expressed as a percentage of IPV 
activity in the vaccine casting solution. In each set of bars, the first bar shows IPV 
activity in MN patch after air drying followed by lyophilization and the second bar 
shows the IPV activity after storage at 40 °C for 1 week with desiccant. Asterisk (*) 
depicts a significant difference between IPV activity compared to other two ratios 
(ANOVA, p < 0.05). Data represent mean ± SEM of n= 3 replicates. Companion 
data on IPV types 1 and 2 are show in Figure A-4 in Appendix A.  
 
4.3.4 Effect of drying conditions  
Solid MN patches are formed by drying the cast formulations in the MN mold. As the 



























can decrease its specific antigenicity, where the antigen’s physicochemical environment 
affects antigen stability during the drying and subsequent storage processes[51]. 
Formulation with polyols such as D-sorbitol and polysaccharides such as maltodextrin, as 
well as drying at controlled temperature and/or by lyophilization, which influence the final 
water content of the MN patch, can maintain antigen activity during drying[144].To study 
the effect of drying temperature and lyophilization, the residual moisture content of MN 
patches were measured by TGA and the IPV activity was measured by ELISA after air 
drying, after subsequent lyophilization, after storage at 40 °C (without lyophilization), and 
after storage at 40°C (with lyophilization).  
 The kinetics of water removal from MN patches depended on drying temperature 
and in some cases, lyophilization, but in all cases the final residual water content after patch 
storage at 40 °C for one week with desiccant was ~2.5%, suggesting an equilibrium state 
of water partitioning between the patch, surrounding air and desiccant at that temperature, 
MN patch formulation and desiccant type (Figure 4-5).  
 Concerning kinetics, residual moisture content of MN patches depended on 
temperature during initial air drying with desiccant for 2 days, where drying at 40 °C, 25 
°C and 5 °C resulted in significantly different residual moisture contents of 3.6%, 6.0% 
and 10.9%, respectively (one-way ANOVA, p <0.0004) (Figure 4-5A).  Lyophilization 
after air drying reduced residual moisture content after air drying at 5 °C (Student’s t-test, 
p < 0.015), but had no significant effect on residual moisture content after air drying at 25 




Figure 4-5: A) Effect of air drying, subsequent lyophilization and storage conditions 
on residual moisture content of MN patches. MN patches were fabricated and air 
dried at 5 °C, 25 °C or 40 °C with desiccant for 2 days. Half of the patches were 
stored at 40 °C for 1 week with desiccant. The other half of the patches were 
subjected to lyophilization followed by storage at 40 °C for 1 week with desiccant. In 
each set of bars, the first bar shows residual moisture content of MN patch after 
initial drying, the second bar shows the residual moisture content after subsequent 
lyophilization, the third bar shows residual moisture content for MN patches stored 
at 40 °C for 1 week with desiccant (no lyophilization) and the last bar shows residual 
moisture content for MN patches stored at 40 °C for 1 week with desiccant after 
lyophilization. Hash (#) depicts no statistical difference between the two samples (1-
way ANOVA, p > 0.05).  B) Effect of air drying, subsequent lyophilization and 
storage conditions on IPV type 3 activity. All IPV activity is expressed as a 
percentage of IPV activity in the liquid casting solution.  In each set of bars, the first 
bar shows IPV type 3 activity in MN patches after air drying, the second bar shows 
the activity after lyophilization, the third bar shows activity for MN patches stored 
at 40 °C for 1 week with desiccant (no lyophilization) and the last bar shows the 
activity for MN patches stored at 40 °C for 1 week with desiccant after 
lyophilization. Hash (#) depicts no statistical difference between the two samples (1-
way ANOVA, p > 0.05). Asterisk (*) indicates a significant difference in IPV activity 
(1-way ANOVA, p < 0.05). Data represent mean ± SEM of n= 3 replicates. 
Companion data on IPV types 1 and 2 are show in Figure A-5 in Appendix A.  
 
Air drying at 5 °C or 25 °C resulted in similar IPV activities (1-way ANOVA, p>0.05), 
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(1-way ANOVA, p<0.05) (Figure 4-5B and Figure A-5 in Appendix A). This is consistent 
with literature, which reports that heating IPV results in loss of D-antigenicity[145]. After 
storage at 40 °C for one week with desiccant (with or without prior lyophilization), IPV 
stability was similar when previously air dried at 5 °C or 25 °C, but was lower when 
previously dried  at 40 °C. We therefore selected air drying at 25 °C (since it dries faster 
than at 5 °C) without lyophilization (since it adds time, cost and complexity with no 
apparent advantage in IPV stability) as the preferred MN patch drying method. 
 
4.3.5 Polio MN patch characterization 
Based on the optimization of 1st cast solution, 2nd cast solution and the drying conditions, 
we fabricated MN patches comprised of a 10 x 10 array of MNs measuring approximately 
650 µm in height (Figure 4-6A). Upon pressing the MN patches to porcine cadaver skin, 
leaving them in place for 15 min and then removing them, microscopic imaging of the 
patch showed that the MNs had substantially dissolved, indicating successful skin 
penetration and dissolution (Figure 4-6B). Staining sites of skin penetration further 
demonstrated that the MNs had punctured the skin (Figure 4-6C). These findings show that 
a formulation optimized for IPV stability was also strong enough to penetrate skin and 





Figure 4-6: MN patch containing a 10 x 10 array of microneedles was manually 
inserted into shaved porcine cadaver skin and imaged (A) before insertion and (B) 
15 min after  
 
4.3.6 Long- term stability of polio MN patches 
The next step was to determine stability of MN patches during long-term storage up to 1 
year at up to 40 °C.  Extended storage at elevated temperatures was studied because 
reduced need for a cold chain of storage is desirable, especially in polio-endemic countries 
which often have poor infrastructure. Consistent with literature[146],storage of 
commercial IPV at an elevated temperature of 40 °C led to complete loss of activity within 
days to weeks (Figure A-6 in Appendix A).  
 MN patches, however, were able to retain IPV activity much better than liquid 
vaccine. All three IPV serotypes maintained >70% activity after 2 months and >50% 
activity after 1 year storage at 5 °C or 25 °C with desiccant (Figure 4-7). It is notable that 
stability at 25 °C was as good as 5 °C. Storage at 40°C was not as good, but yielded >40% 
 
 
activity after 2 months and >20% activity after 1 year for all three serotypes. We are not 
sure why IPV stability at the one-week time point was lower than the overall trend would 







Figure 4-7:  IPV activity in MN patches stored at 5, 25 or 40 °C with desiccant for 
up to 1 year. MN patches were analyzed using ELISA for (A) IPV type 1, (B) IPV 
type 2 and (C) IPV type 3 activity at various time points. IPV activity is expressed as 
a percentage of IPV activity of MN patches immediately after fabrication. Data 
represent mean ± SEM of n= 3 replicates. 
4.3.7 Correlation of residual moisture content in patch to IPV stability 
Our studies so far indicated that IPV instability was driven by elevated temperature 
(especially at 40 °C). However, IPV instability could also be caused by presence of water, 
which is a potent plasticizer because of its low glass transition temperature (Tg  = -135 °C) 
[147], which can facilitate reactions controlled by molecular mobility, such as protein 
unfolding, aggregation and chemical degradation. We therefore prepared and stored MN 
patches at various temperatures and humidity levels to generate patches with a range of 


















































Figure 4-8: A) Effect of storage conditions on residual moisture content of polio MN 
patches stored at 5, 25 or 40 °C with desiccant or at 40 °C and 50% relative 
humidity (RH). B) Correlation of IPV type 3 stability in MN patches to residual 
moisture content of the patches stored at 5, 25 or 40 °C with desiccant or at 40 °C 
and 50% relative humidity (RH). Regression analysis showed an R2 value of 0.009, 
indicating poor correlation.  Data represent mean ± SEM of n= 3 replicates. 
Companion data on IPV types 1 and 2 are show in Figure A-7 in Appendix A. 
 
 Residual moisture content of MN patches immediately after fabrication was 6.6 ± 0.2%. 
Storage at different temperatures for different times produced patches with residual 
moisture contents as low as 1.3 ± 0.1%. Storage at 5°C, 25°C or 40 °C for 1 month with 
desiccant resulted in moisture loss of 2%, 4% or 5%, respectively. Storage at 40 °C and 
50% RH resulted in minimal moisture loss of 0.5%. 
 At these different times and temperatures, IPV activity loss ranged between 91% 
and 7%. Correlation between IPV activity and residual moisture content (independent of 
temperature) was poor (Figure 4-8B and Figure A-7 in Appendix A), with R2 values of 
<0.05. In contrast, there was a correlation (R2 values of 0.38 – 0.67) between IPV activity 
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shows that IPV destabilization processes are driven by elevated temperature with little 
influence from residual moisture content over the range of conditions studied. 
 
4.3.8 Characterization of changes in MN matrix material properties during patch 
storage 
Interaction between IPV and the excipients that make up the MNs could play a role in IPV 
activity loss. Because there can be mixing of 2nd cast excipients with 1st cast excipients 
during the MN fabrication process, we determined the composition of MNs (i.e., without 
the patch backing).  Because gelatin was present only in the 2nd cast formulation and was 
the only protein in either formulation, we measured the amount of protein in MNs separated 
from patch backing and used that to calculate the amount of 2nd cast formulation that had 
mixed with the 1st cast formulation in the MNs. In this way, we determined the composition 
of MNs was 55% fish gelatin, 38% D-sorbitol and 7% maltodextrin, on a mass basis. To 
study changes in material properties in MNs during storage, we cast samples with this 
composition and stored them at 5 °C, 25 °C or 40 °C with desiccant and then characterized 
them as described below.  
 
4.3.8.1 Determination of glass transition temperature of MNs by DSC 
MNs stored below their Tg will be in an amorphous glass phase, which has high viscosity 
that can retard vaccine mobility and interactions and prevent crystallization, both of which 
can cause IPV instability[148].  Using DSC to determine Tg, we found that the MN matrix 
 
 
initially had a Tg of 48 °C, which increased over time to as much as 59 °C (Figure 4-9). 
This finding is consistent with our prior observation that residual moisture content 
decreased with storage time (Figure 4-8A), since a decrease in moisture content is generally 
associated with an increase in Tg [52]. These data may also explain why stability at 5 °C 
and 25 °C are similar, since they are both well below the Tg, but stability was worse at 40 




Figure 4-9: Effect of storage time and temperature on Tg of MN matrix material 
measured by DSC. Tg was measured at specific times for up to 30 days at 5 °C, 25 
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4.3.8.2 Determination of chemical composition changes of MNs by FTIR 
We next used FTIR to study possible changes in molecular structure, chemical bonding 
and molecular environment in the MN matrix after 30 days at 5 °C, 25 °C or 40 °C (Figure 
4-10). The spectra appear very similar, which means that chemical changes were not 
detected among the samples.  In contrast, the long term stability study showed greater IPV 
instability at 40 °C when compared to 5 °C, and 25 °C. Hence, the lack of changes in 
molecular level interactions between IPV and excipients determined by FTIR could not be 
correlated to IPV instability. 
  We interpret the peaks situated at 3272-3370, 1627- 1632, 1532-1546 and 1235-1276 cm 
-1 to correspond to N-H stretching and free water, amide I, amide II and amide III, 
respectively[149]. We further interpret amide I to represent C=O stretching/hydrogen 
bonding coupled with COO; amide II to represent bending vibration of N–H groups and 
stretching vibrations of C-N groups; and amide-III to be related to the in-plane vibrations 
of C-N and N-H groups of bound amide or vibrations of CH2 groups of proline side chains 
in gelatin[150]. The strong peak between 4000-3200 cm-1 and the peak at 1081 cm−1 are 
believed to be mainly from –OH stretching and C-O stretching vibrations from D-sorbitol 





Figure 4-10: FTIR spectrum of MN matrix samples measured 30 days after storage 
at 5 °C, 25 °C or 40 °C with desiccant. Data represents averages of n= 3 replicates.  
 
4.3.8.3 Determination of matrix structural changes in MN by XRD 
XRD was performed to better understand structural changes in the MN matrix (Figure 
4-11).  The broad peak centered near 2θ = 20° observed in all samples indicates that the 
MN matrix is in an amorphous phase[152], which we interpret to be mainly composed of 
gelatin and maltodextrin based on the XRD patterns of the individual materials (Figure A-9 
in Appendix A). The fresh and 1 week samples also show a sharp peak at approximately 
2θ = 42-43°, which suggest an additional crystalline phase probably composed of D-
sorbitol. The intensities and peak areas for fresh and 1 week samples were similar 
independent of the storage temperature. After 1 month, however, the crystalline peak 
heights for all the samples decreased by ~ 76% and the peak areas decreased by ~ 83%. 
This suggests that the MN matrix became more amorphous during storage, as residual 
water content decreases and Tg increases independent of the storage temperature. Since the 
long term stability study showed greater IPV instability at elevated temperature, we 
 
 
conclude that the changes observed in the bulk matrix properties could not be correlated to 
the IPV instability. 
 
Figure 4-11:  X-ray diffraction patterns corresponding to MN matrix samples stored 
at 5 °C, 25 °C or 40 °C for up to 30 days. Data represent averages of n= 3 replicates. 
 
4.4 Discussion 
The WHO has recommended replacing OPV with IPV worldwide to eliminate the risk of 
vaccine-derived polioviruses[131]. However, IPV as currently provided as a liquid 
administered by IM injection, has certain limitations such as the need for trained healthcare 
personnel, risk of transmission of blood-borne infectious diseases[24] from the sharps 
waste and the need for cold chain to avoid loss of IPV potency. MN patches can improve 
IPV delivery by enabling simple administration by minimally trained personnel and 
avoiding generation of biohazardous sharps waste[153]. In this study, we optimized MN 
















patch formulation to improve IPV stability during extended storage at elevated 
temperatures. 
 Initial formulation optimization studies showed that a combination of maltodextrin 
and sorbitol was optimal for minimizing IPV loss during drying. Buffer screening showed 
that histidine buffer at pH 6 was optimal for IPV stability. Guided by these findings, MN 
patch optimization studies identified a 1st cast composition of maltodextrin:D-sorbitol ratio 
of 20:80 (on a dry basis) and a 2nd cast composition of fish gelatin: D-sorbitol at ratio of 
77:22 (on a dry basis, when cast as 45% w/v solids in solution) that provided the best 
stabilization of all three types of IPVs and produced MN patches with strong microneedle 
tips. Drying temperature optimization studies showed that air drying of the MN patches at 
25 °C was effective, and subsequent lyophilization did not show any significant 
improvement in IPV stability.  
 The MN patch fabrication process is relatively simple and scalable to the potential 
demands for many millions of patches per year required by the polio eradication program. 
The IPV patches were tested in pig cadaver skin and found to insert into skin by thumb 
without the need for an applicator. This simple application process can enable 
administration by minimally trained personnel, thereby reducing costs by reducing the need 
for healthcare professionals. This simplified administration could facilitate more efficient 
mass IPV vaccination campaigns and routine IPV vaccination too. The inserted patches 
also showed near-complete MN dissolution in the skin within 15 min. This MN dissolution 
has the potential to eliminate the risks of biohazardous sharps. Finally, the MN patch was 
demonstrated significant thermostability even at 25 °C for up to 1 year (> 50% activity) or 
at 40 °C for up to 2 months (> 40% activity). This thermostability could aid reduce reliance 
 
 
on cold chain storage, especially for short periods of time (days to weeks) during 
vaccination campaigns and transport to remote locations. This collection of capabilities 
represents a significant advanced that can overcome many of the hurdles posed by the 
transition from OPV to IPV. 
 Mechanistic studies were performed to understand the effect of MN matrix 
properties on IPV activity during storage. Residual moisture content of the patches 
decreased with increase in storage temperature but no correlation was seen between 
moisture content and IPV stability. MN patches showed an increase in Tg with increase in 
storage temperature, which was consistent with the moisture loss determined by TGA (i.e., 
where moisture loss correlates with increased Tg). This suggests that the MN matrix 
become more amorphous at elevated storage temperature and over time. XRD results also 
showed an increase in amorphousness of the matrix upon extended storage. Even though a 
more amorphous (i.e., glassy) matrix should retard diffusion-controlled reactions such as 
protein unfolding, and aggregation, IPV was less stable at elevated temperature and longer 
storage times (both of which promote diffusion-controlled, and most non-diffusion-
controlled, reactions).  Because none of these trends in macroscopic MN matrix changes 
correlated with changes in IPV activity, we hypothesize that molecular-scale interactions 






This study presents the development of a dissolving MN patch for IPV vaccination. 
Formulation and process optimization studies were performed to identify an excipient 
combination and drying condition during MN patch fabrication that minimized IPV activity 
loss. The MN patch was simple to administer; generated no sharps waste; and maintained 
significantly improved thermostability during extended storage at elevated temperature 
compared to conventional liquid IPV. When stored with desiccant, IPV in MN patches 
maintained >70% activity after 2 months and >50% activity after 1 year at 5°C or 25°C , 
and maintained >40% activity after 2 months and >20% activity after 1 year at 40 °C. 
Changes in MN matrix properties such as residual moisture content, Tg and crystallinity 
were measured, but did not correlate with changes in IPV activity. These findings suggest 
that a MN patch could enable increased thermostability and other advantages important to 
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CHAPTER 5. RECRUITMENT AND COLLECTION OF DERMAL 
INTERSTITIAL FLUID USING A MICRONEEDLE PATCH 
5.1 Introduction 
There is rapidly increasing interest in personalized medicine and point-of-care diagnostics 
using novel biomarkers[154,155]. Blood is the primary source of body fluid containing 
these biomarkers. However, blood sampling by venipuncture is painful and requires trained 
medical professionals, while capillary blood sampling can be variable[156]. Alternate body 
fluids such as urine and saliva are more easily accessible but have their own limitations 
such as variability in urine biomarker concentrations due to circadian variations[67] and 
interference in saliva-based assays by food or drugs[69]. 
 Interstitial fluid (ISF) is a relatively unexplored body fluid that is a rich source of 
biomarkers[7,77] that does not clot[79]. ISF comprises 15-25% of total body weight[74] 
and is formed by transcapillary exchange during blood flow. It fills extracellular space in 
tissues, which means that ISF biomarkers can provide systemic information due to its 
origins in blood and local information due to its contact with cells in tissues. Proteomic 
and metabolomics analysis of ISF from skin has shown that it has many biomarkers in 
common with companion serum and plasma samples, but also contains many other 
biomarkers that are unique or at much higher concentration compared to serum and plasma 
[6,7,121,157,158,159].  
 Some of the methods for ISF sampling include suction blister[82], which takes ~1 
h to perform and leaves a lasting wound; reverse iontophoresis[98], which requires 
 
 
calibration using blood samples and proprietary instrumentation; and microdialysis[94] 
and open-flow microperfusion[95], which require minor surgery and significant expertise. 
In large part because of the limitations of these methods, very few studies have examined 
ISF, and information on ISF properties and composition (other than glucose concentration) 
is extremely limited.  
 An alternate approach to collect ISF involves the use of microneedles (MNs), which 
are solid, tapered structures measuring hundreds of microns in length that painlessly 
penetrate into tissue, such as skin. MN patches were developed initially for delivery of 
vaccines and drugs, where they have been shown to be safe and simple to administer 
[29,160,161,162] . MNs have also been used to puncture the skin and collect a microliter 
quantities of ISF under suction[110,121], by passive diffusion through MN bore or built-
in sensors[109,111,112], using MNs coated with capture antibodies to collect specific 
antigens[114,115] and with MNs made of swellable hydrogel that absorb ISF from the 
skin[118-120].  While ISF collection using MNs can be simple, minimally invasive and 
well-tolerated, most approaches are time consuming, requiring 15 - 30 min. The goal of 
this study is to develop a simple and easy-to-use MN patch that can collect ≥1 µl of ISF 
within 1 min.  
5.2 Materials and methods 
5.2.1 Microneedle patch fabrication 
MN patches were cut from stainless steel sheets (Trinity Brand Industries, SS 304, 100 μm 
thick; McMaster-Carr, Atlanta, GA) using an infrared laser (Resonetics Maestro, Nashua, 
NH), as described previously[132]. The desired dimensions were drafted using AutoCAD 
 
 
software (Autodesk, Cupertino, CA). MN patches were cut using the infrared laser at 1000 
Hz, 20 J/cm2 energy density and 40% attenuation of laser energy. A total of three passes 
were required to completely cut through the stainless steel sheet. A cutting speed of 2 mm/s 
and air purge at a constant pressure of 140 kPa were used. The MN patches were 
electropolished using an electropolishing solution (E972, ESMA, South Holland, IL) in an 
electropolisher (E399, ESMA) for 5 min at 2 A and room temperature. The electropolished 
array (each MN having final dimensions of 750 µm in length, 100 µm x 70 µm in cross 
section and tapering to a tip of <1 µm radius of curvature) was rinsed with isopropyl 
alcohol, cleaned with DI water and air dried.  
 MN patches were also prepared by lithographically defined chemical etching by 
Tech Etch (Plymouth, MA). Patches comprised either 5 MNs (750 µm long) or 9 MNs (650 
µm) each measuring 50 µm x 150 µm in cross section and tapering to a tip of <1 µm radius 
of curvature. 
 
5.2.2 MN surface pretreatment 
5.2.2.1 Hydrophilic plasma treatment 
To create a hydrophilic surface, MN arrays were air plasma treated by placing them in a 
plasma chamber (PDC-32G, Harrick Plasma, Ithaca, NY) for 5 min at the maximum radio 





5.2.2.2 Hydrophobic Parylene coating 
To create a hydrophobic surface, MN patches were coated with a conformal vapor 
deposition of 1 µm thick (using 1.6 g of dimer) Parylene C coating using a SCS Labcoater 
PDS 2010 (Specialty Coating Systems, Indianapolis, IN). 
 
5.2.3 Paper reservoir 
A strip of paper was adhered to the backing of each MN patch to create a reservoir to collect 
ISF that flowed out of the skin during MN insertion. For initial screening of paper for this 
application, samples of banana fiber paper, cotton fiber paper, and blotter paper were 
generously provided by the Renewable Bioproducts Institute (Georgia Institute of 
Technology, Atlanta, GA). Copy paper (Staples, Framingham, MA) and Whatman grade 1 
filter paper (Sigma Aldrich, St. Louis, MO) were used as received. 
 The filter paper was ultimately selected as the material to use to form the reservoir. 
Filter paper strips were cut into rectangular strips of desired dimensions (1 mm x 7 mm or 
2 mm x 7 mm) using a CO2 laser (New Hermes Gravograph Model LS500XL, Gravotech, 
Duluth, GA).  The patterns were made using a vector cut at 24 W power and a speed of 8 
mm/s.  To prevent excessive temperature rise that could cause burning during laser cutting, 
the filter paper was attached to an adhesive backing (3M, Maplewood, MN) first and 
soaked in DI water until completely wet to increase heat capacity. 
 The final MN patch was prepared by adhering the filter paper to the MN patch 
backing without covering the MNs.   
 
 
5.2.4 Modified Cobb and Klemm methods for determining water absorptiveness of paper 
The water absorptiveness of different types of paper was determined by modified Cobb 
(ISO 535:2014)[163] and Klemm (ISO 8787:1986)[164] methods. The modified Cobb 
method was performed by weighing each paper (precut to 10 cm x 1 cm strips) before 
soaking in 10 ml of deionized (DI) water for a specified amount of time. The paper was 
gently pressed to remove excess water and then reweighed. The Cobb value, which is the 
measure of water absorptiveness, is equal to the difference in the weight of the sample 
before and after soaking. Cobb values were normalized to the initial paper mass to account 
for thickness differences between the paper strips. 
 The modified Klemm method, which is a measure of capillary rise, was performed 
by vertically suspending a 10 cm x 1 cm rectangular strip of each paper sample so its lower 
edge just touched the surface of 10 ml of DI water in a beaker for a specified amount of 
time. The distance that water travelled up the strip was measured using a ruler. The 
obtained Klemm values were normalized to the initial weights of the samples to account 
for thickness differences between the papers. 
 
 
5.2.5 Contact angle measurements 
Static contact angle measurements were made placing 2 µL of DI water on plasma-treated, 
Parylene-coated and untreated MN surfaces by a goniometer (model 250, Rame’-hart 
 
 
Instrument, Succasunna, NJ). Contact angle measurements are reported as the mean value 
of six measurements under the same conditions.  
 
5.2.6 Quantification of ISF volume collected 
The amount of ISF collected was quantified by determining sodium ion content in the MN 
patch paper backing using a sodium ion sensitive electrode (perfectION comb NA, Mettler 
Toledo, Columbus, OH). Paper backings were each incubated in 1 ml of DI water for 24 h 
at room temperature (21 – 25 °C) to extract solutes from ISF that at least partially dried on 
the paper. The sodium ion content measured in the samples was divided by the 
physiological sodium ion concentration in rat ISF of 143 mEq/L [165] to determine ISF 
volume collected. This method relies on the expectation that sodium ion concentration is 
constant in the ISF of normal rats[166]. 
 
5.2.7 ISF collection from pig skin ex vivo 
Pig ear skin was obtain freshly excised from feeder pigs (generously provided by Hollifield 
Farms, Conyers, GA) and then kept frozen at –80°C until use. Circular skin samples (2 cm 
diameter) were thawed and placed in vertical Franz diffusion cells (PermeGear, Bethlehem, 
PA). The donor chamber (on the top of the diffusion cell) was sealed using Parafilm 
(Bemis, Neenah, WI). The receptor chamber (on the bottom of the diffusion cell) was filled 
with 5 ml of 1 mg/ml fluorescein sodium salt (Sigma Aldrich) in DI water. The Franz cells 
 
 
were placed overnight in a heating blocking (PermeGear) set to 37 °C to equilibrate the 
skin with the fluorescein solution.  
 The skin samples were removed from the Franz cells and then stretched and secured 
on a board using push pins. The MN patches were inserted with a force of 20 – 40 N for a 
specified number of times. Fluorescence imaging of the skin was performed using an 
Olympus SZX2 stereo microscope with a CCD camera (Leica DC 300, Leica 
Microsystems, Bannockburn, IL).  
 Paper backings were each incubated in 1 ml of DI water for 24 h. The fluorescein 
concentration in the reconstituted ISF samples was measured against a standard calibration 
curve of fluorescein in a 96 well plate (Costar Black Polypropylene, Corning, Corning, 
NY) using a Synergy H4 hybrid reader (BioTek, Winooski, VT) at an emission wavelength 
of 525 nm and absorption wavelength of 590 nm. The amount of ISF collected was 
calculated as the measured fluorescence content from the ISF divided by the known 
fluorescein concentration in skin, i.e., 1 mg/ml. 
 
5.2.8 ISF collection from rat skin in-vivo  
5.2.8.1 In-vivo study design 
Fifteen Wistar rats (10-20 weeks old, female, Charles River Laboratories, Wilmington, 
MA) were anesthetized by isoflurane (AErrane, Baxter Healthcare, Deerfield, IL) 
inhalation in a prone position, during which all procedures were performed. A section of 
hair on the lateral side of the rat was removed using electric shears followed by brief 
 
 
application of depilatory cream (Nair, Princeton, NJ), and then cleaned with gauze and DI 
water.  The hair removal was performed at least 1 day prior to ISF collection to avoid 
possible ISF contamination by the depilatory cream. The rats were randomly divided into 
3 groups, as shown in Figure 5-1.  After each experiment, the rat was euthanized by carbon 
dioxide gas asphyxiation. These experiments have been approved by the Georgia Institute 
of Technology Institutional Animal Care and Use Committee.  
  
Figure 5-1: Experimental plan for study to determine the effect of skin pre-
treatment on the amount of ISF collected from rat skin in vivo. Group 1 only 
received MN treatment to collect ISF, in which a MN patch containing 9 MNs with a 
2 mm x 7 mm piece of filter paper glued on the patch backing was applied 10 times 
to the skin on the lateral side of the rat using a force of 20 – 40 N. Group 2 skin was 
pretreated with a MN patch backing with MNs cut off to provide a blunt 
pretreatment, followed by MN treatment to collect ISF after a 5 min delay. Group 3 
followed the same protocol as Group 2, except sharp-tipped MNs were used during 
the pretreatment. Each treatment was performed on 3 sites per rat. 
 
15 female Wistar rats
Group 1
MN treatment only
Insert MN patch into skin 
10 times to collect ISF, 
and biopsy immediately.
Biopsy skin from other 
side of rat as untreated 
control skin. 
Group 2
Blunt  pretreat + MN treatment
Press blunt MN patch backing 
against skin 10 times, wait 5 min, 
insert MN patch into skin 10 
times to collect ISF, and biopsy 
immediately. 
Biopsy skin from other side of rat 
as untreated control skin. 
Group 3
MN  pretreat + MN treatment
Insert MN patch into skin 10 
times to collect ISF, wait 5 min, 
insert MN patch into skin 10 
times to collect ISF, and biopsy 
immediately.
Biopsy skin from other side of 
rat as untreated control skin




5.2.8.2 Determination of total water content of skin  
To measure ISF content in the skin, pieces of rat skin were pre-weighed (60- 140 mg per 
piece) immediately after biopsy and lyophilized (Freezone 6 liter freeze dryer, Labconco, 
Kansas City, MO), as described previously[167].The mass loss after lyophilization was 
taken to equal the ISF content in the skin, assuming complete water removal by 
lyophilization. The percent increase in hydration due to skin pretreatment was determined 
as the difference between the water content of treated and control skin samples normalized 
to the water content of the control skin. 
 
5.2.8.3 Imaging and histology 
Skin biopsies were embedded in Optimum Cutting Temperature (OCT) media (Tissue-Tek, 
Torrance, CA) in a cryostat mold. Samples were fixed by freezing on dry ice. Frozen 
samples were sliced into approximately 6 μm thick sections using a cryostat (Cryo-star HM 
560MV, Microm, Waldorf, Germany) and placed on glass slides. Hematoxylin and eosin 
(H&E) staining was performed on the skin sections using an automated staining machine 
(Leica Autostainer XL, Nussloch, Germany). A few drops of cytoseal 60 (low viscosity, 
Richard-Allan Scientific, Kalamazoo, MI) were applied onto the stained skin sections. The 
samples were then covered with glass cover slips and dried in a fume hood overnight. 
Imaging was performed using a Zeiss AxioObserver Z1 fluorescence microscope (Carl-




5.2.9  Statistical analysis 
Statistics were calculated using either MiniTab software version 18 (MiniTab, State 
College, PA). or Excel (Microsoft, Redmond, WA). All listed averages represent the 
arithmetic mean of the samples. Comparison between three or more samples was 
performed by one-way ANOVA or 2-way ANOVA. Comparisons between individual 
samples were done using an unpaired t-test. Probability (p) values of <0.05 were considered 
to be significant. 
 
5.3 Results 
5.3.1 Microneedle patch design  
The MN patch was designed as a two-component system comprising a strip of paper (which 
serves as an ISF reservoir) on the backing of a stainless steel MN array (which creates 
micropores in the skin through which ISF can flow to the skin surface) (Figure 5-2A,B). 
To collect ISF, the MN patch was repeatedly applied to the skin surface, thereby inducing 






Figure 5-2: Representative images of MN patch for ISF collection. A) A patch 
comprising a row of nine microneedles (arrow) with a strip of white filter paper 
adhered to the patch backing. B) Magnified image of a single microneedle. C) Image 
of ISF collection after 5 insertions of a MN patch in the skin of a hairless rat in vivo. 
The MNs are on the lower edge of the patch and cannot be seen because they are 
inserted into the skin. Clear ISF is collected in the paper reservoir as observed by 
wetness of the paper (arrow). 
 
The amount and speed of ISF collection could depend on the absorptiveness of the paper 
reservoir. We tested five different types of papers as candidate reservoir materials and 
measured their absorptiveness by modified Cobb and Klemm methods (Figure 5-3). Both 
methods indicated that the banana fiber paper was the most absorbent of all the tested 
papers, followed by filter paper. We chose filter paper for further optimization because of 
its ease of availability, low cost and widespread use by many researchers for development 
of paper-based sensor devices[168,169].  
 To calibrate the volume of ISF that filled reservoirs of filter paper, we inserted MN 
patches into the skin of anesthetized hairless rats until the reservoirs were completely 
wetted with ISF, as determined by visual examination. Rectangular strips of filter paper 
cut into 1 mm x 7 mm or 2 mm x 7mm strips collected 1.1 ± 0.3 µl and 2.0 ± 0.2 µl of ISF, 
respectively (mean ± standard error of the mean, n = 6 replicates).  
 
 
   
Figure 5-3: Water absorptiveness of different types of paper determined by 
modified Cobb method and modified Klemm method. (A) For the Cobb method, 10 
cm2 paper strips were weighed before and after soaking in DI water for 30, 60, 90 
and 120 s. The Cobb value is the amount of water absorbed by the paper 
normalized to the initial paper mass to account for thickness differences between the 
paper strips. (B) For the Klemm method, 10 cm2 paper strips were suspended 
vertically with their lower end immersed in 10 ml of DI water for 30, 60, 90 and 120 
s. The Klemm value is the capillary rise of water determined by measuring the 
vertical distance travelled by water. The Klemm value was normalized to the initial 
paper mass to account for thickness differences between the paper strips. Data 
represents mean ± SEM (standard error of the mean) of n= 3 replicates. 
 
5.3.2 Effect of multiple skin insertions, number of MNs per patch and MN thickness on 
ISF collected 
We optimized ISF collection by studying the effect of MN parameters on amount of ISF 
collected from pig ear skin ex vivo, which was artificially hydrated with fluorescein to 
facilitate quantification of ISF collected). We found that the amount of ISF collected 
increased by increasing the number of skin insertions by MNs from 1 to 20 insertion, 














































































9 MNs per patch (three-way ANOVA, p < 0.03) (Figure 5-4). Increasing number of skin 
insertions and number of MNs per patch both should increase the number of microscopic 
channels for ISF to flow out of skin. Puncturing skin with thicker microneedles should 
result in larger micropores, thereby allowing easier access to ISF. 
 
  
Figure 5-4: Effect of microneedle (MN) patch design on the amount of ISF collected. 
Patches were prepared with MN measuring either 50 µm or 100 µm in thickness and 
comprising either 5 or 9 MNs per patch. ISF was collected by applying a MN patch 
1, 3, 5 or 20 times to stretched pig ear skin ex-vivo artificially hydrated with 























No. of skin insertions
5 MN/array, 50 µm thick
5 MN/array, 100 µm thick
9 MN/array, 50 µm thick
 
 
5.3.3 Effect of MN surface properties on ISF collected 
Improving the wettability of the stainless steel MN surface could expedite ISF collection 
time by facilitating ISF flow on the MN surface to the paper reservoir. To test this 
hypothesis, we treated the MN patch with air plasma or coated the MN patch with Parylene 
C to render the MN surface more hydrophilic or hydrophobic, respectively, as shown 
through contact angle measurements (2-way ANOVA, p < 0.001) (Figure 5-5). While it 
required 15 skin insertions to collect 2 µl of ISF from hairless rat skin in vivo when using 
MN patches with no surface modification, increasing hydrophilicity of the MN surface 
decreased the required number of skin insertions to 10, whereas increasing hydrophobicity 
increase the number of skin insertions to 18  (Figure 5-5). This indicates that ISF collection 
involves fluid flow on the MN surface and that surface tension of the MN surface thereby 




















































Figure 5-5:  Effect of microneedle (MN) surface properties on ISF collection from 
skin. MN patches made of stainless steel (type 304) were (i) treated with air plasma 
for 5 min to increase hydrophilicity (ii) untreated or (iii) coated with 1 µm thick 
Parylene C to impart hydrophobicity. The y axis shows sessile drop contact angle of 
water of the MN surfaces and the secondary y-axis shows the number of insertions 
required to collect 2 µl of ISF from hairless rats in vivo.  Asterisk (*) and cross (†) 
identify values significantly different from the corresponding value with no 
coating/treatment for mean contact angle and # skin insertions, respectively (2-way 
ANOVA p < 0.01). Data represent mean ± SEM (standard error of the mean) of n= 
6 replicates. 
 
5.3.4  Effect of skin pre-treatment on ISF collected 
We have generally observed that very little ISF comes out of the skin during the first few 
MN insertions, and the more comes out as the number of insertions increases. This led us 
to hypothesize that the act of collecting ISF (e.g., piercing the skin with MNs) affects the 
rate at which ISF comes out of the skin, possibly by increasing skin hydration, which is 
known to increase hydraulic conductivity of tissues by increasing the spacing by tissue 
fibers (e.g., glycosaminoglycans making up extracellular matrix, collagen fibers in 
dermis)[170]. This hypothesis is supported by our visual observation of local edema in skin 
after ISF collection by MN patch (data not shown). 
 To test this hypothesis, ISF was collected from a first group of rats using 10 skin 
punctures with MN patches following our standard protocol (Group 1, see Figure 5-1). In 
a second group of rats, the skin was pre-treated with a blunt MN patch backing to simulate 
the mechanical interaction between MN patches and skin without the MN puncture into 
skin. No ISF was collected during this blunt pre-treatment (Figure 5-6A). After 5 min, ISF 
was collected using our standard protocol of 10 MN patch insertions into skin (Group 2). 
There was no significant effect of this blunt MN patch pretreatment on the amount of ISF 
 
 
collected 5 min later (Figure 5-6A).  In a third group of rats, the skin was pre-treated using 
the standard protocol of 10 MN patch insertions, which was followed 5 min later with 
another 10 MN patch insertions using our standard protocol to collect ISF (Group 3). The 
amount of ISF collected during the pre-treatment was not significantly different from the 
amount of ISF collected in Group 1 (Figure 5-6A). However, the amount of ISF collected 
when the identical treatment was performed 5 min later collected 4.3 times more ISF 
(Figure 5-6A). This results suggests that the act of collecting ISF by MN patch skin 
puncture affects the skin so that continued ISF collection is easier.  
 The percent increase in skin water content was measured immediately after 
treatments in the three test groups. In Group 1, skin hydration increase by 5%, presumably 
due to the effects of MN patch skin puncture (Figure 5-6B). When the blunt pre-treatment 
was performed in Group 2, skin hydration significantly increased to 12% after subsequent 
MN patch skin puncture (Figure 5-6B), even though ISF collection data did not indicate an 
effect of blunt pre-treatment Figure 5-6A). However, rats in Group 3 that received a sharp-
tipped MN patch pre-treatment, exhibited a 21% increase in skin hydration after the 
subsequent MN patch skin puncture (Figure 5-6B), which was associated with a large 
increase in ISF collection (Figure 5-6A) and supports the hypothesis that MN patch skin 
puncture increases skin hydration which can be associated with increased rates of ISF 
collection.  
 Visual observation of the skin immediately after 10 MN patch skin punctures did 
not show evidence of erythema or edema. Very mild erythema appeared 2 - 3 min after the 
skin punctures, which was localized to a small rectangle (~3mm by ~1 cm) at the sites of 
MN puncture. The erythema resolved within one day (data not shown). Edema was also 
 
 
seen within 2 – 3 min, which spread over a larger area of ~1 cm2 surrounding the MN 
puncture site. The edema resolved within few hours. Examination of skin sections taken 
from the sites of MN patch skin puncture did not show evidence of inflammatory cells at 
the time of collection (i.e., immediately after MN patch skin puncture) (Figure 5-7).  
   
Figure 5-6: Effect of skin pre-treatment on amount of ISF collected and skin 
hydration. ISF was collected from the skin of shaved Wistar rats in vivo using 10 
skin insertions with MN patches (Group 1), using a pre-treatment of 10 skin 
applications with a blunt MN patch backing (i.e., not expected to puncture skin) 
followed 5 min later by 10 skin insertions with MN patches (Group 2) or using a 
pre-treatment of 10 skin applications with a conventional, sharp-tipped MN patch 
backing (i.e., expected to puncture skin) followed 5 min later by 10 skin insertions 
with MN patches (Group 3), as described in Figure 1. A) Effect of skin pre-
treatment of amount of ISF collected from shaved Wistar rat skin in vivo. B) Effect 
of skin pre-treatment on skin hydration in hairless rats in vivo. Immediately after 
the experiment in Part A, the weight of skin samples biopsied from the skin 
treatment area was measured before and after lyophilization (expected to fully 
dehydrate the skin) to determine hydration level. The percent increase in hydration 
due to skin pretreatment was determined by hydration levels of treated samples 
normalized to untreated control samples. Data represent mean ± SEM (standard 
error of the mean) of n= 15. Asterisk (*) depicts a significant increase in amount of 
ISF collected or percent increase in skin hydration compared to Group 1 (2 way 

























































Figure 5-7:  Representative images of H & E-stained sections of skin from shaved 
Wistar rats after ISF collection shown in Figure 6.The study plan for Groups 1, 2 
and 3 is shown in Figure 1. Sections from skin treated with MN patches (Treated) is 
compared to skin from the same animals at untreated sites (Control). All skin 
samples showed mild signs of immune response, as evidenced by infiltration of 
immune cells (arrows), possibly due to hair removal due to shaving and application 
of depilatory cream. However, no meaningful differences in immune cell infiltration 
was observed between controls and treated samples or between the three test 
groups.  
 
5.4  Discussion 
5.4.1 Design of MN patch for simplified collection of ISF 
ISF is a rich source of biomarkers but has been relatively unexplored due to lack of good 
sampling methods. Current methods like suction blister, microdialysis and open flow 
microperfusion cause significant skin trauma, are time consuming and require expert 
personnel and equipment to perform [92-95,159,171] . This study introduces a novel MN-
based method to collect ISF that causes minimal skin trauma, takes just a few minutes to 
 
 
perform and can be done using an inexpensive MN patch without the need for expert 
training to perform.  
 The MN patch causes minimal trauma because the MNs are of sub-millimeter 
dimensions. We demonstrated that >2 µl of ISF can be collected by inserting MNs up 
to 15 times within 20 s. Even more can be collected after additional insertions (e.g., we 
have collected up to 8 µL by administering 30 MN insertions within 2 min (data not 
shown)). We also demonstrated that microliter volumes of ISF can be collected with 
fewer insertions after skin pre-treatment followed by a 5 min delay. Microliter volumes 
should be sufficient for many assays, like glucose [172], cholesterol[173] and many 
drugs for therapeutic drug monitoring especially in neonates[174]. The MN patch should 
be cost effective when compared to other available ISF collection techniques because 
the cost of materials (stainless steel sheet, filter paper and adhesive) is nominal 
(estimated to cost less than a dollar) and the manufacturing and sterilization processes 
are straightforward. The MN patch is easy to use and does not require trained medical 
professionals for administration. 
 In contrast, conventional ISF collection methods such as reverse osmosis involve 
usage of proprietary equipment and methods such as micro dialysis or micro perfusion 
require minor surgery and significant expertise which can increase the overall cost of 
the collection procedure. 
5.4.2 Factors affecting ISF collection 
MN patch developed in this study consists of a simple two-component system: a stainless 
steel MN patch for puncturing the skin to form micro channels for ISF flow out of the skin 
 
 
and a thin strip of paper to create a reservoir for the ISF.  We tested five different types of 
paper for their water absorptiveness and chose Whatman grade 1 filter paper, which is 
commonly used in research applications for paper-based sensors due to its wicking 
ability[175]. The hydrophilic cellulose fibers in this paper allow ISF to penetrate the matrix 
without the need for active pumping or other driving forces[176]. This paper is also 
commonly functionalized for detection of specific analytes[169].  
 We tested the effect of multiple skin insertions, number of MNs per patch, MN 
thickness and wettability of the MN surface. All of these factors increased in ISF collection, 
enabling collection of >2 µL of ISF within 1 min. The multiple MN insertions facilitate 
ISF collection by increasing the number of pathways out of the skin and by their “pumping” 
action, which avoids the need to apply positive pressure or suction. A recent study showed 
that the rate-limiting step for ISF collection is often transport through the skin to the site 
of MN puncture, such that forces that generate convective flow in the skin can significantly 
facilitate ISF collection[121].  
 
5.4.3 Effects of MN patch puncture on skin 
An interesting finding was that MN patch pre-treatment of the skin followed by a 5 min 
wait time dramatically increased ISF collection. The effect was accompanied by an 
increase in tissue hydration of more than 20%. Because 1 cm2 of skin contains on the order 
of 100 µL of ISF [121], it seems unlikely that the amount of ISF in the skin limited 
collection and just a ~20% increase in hydration increased ISF collection many fold. 
Instead, it is well established that hydraulic conductivity of the interstitial spaces of tissues 
 
 
is low due to resistance provided by extracellular matrix (glycosaminoglycans) and 
collagen fibers. Even a relatively small increase in tissue hydration can increase spacing 
between fibers and thereby increase hydraulic conductivity. This is because volumetric 
flow rate through a porous medium increases with pore radius raised to the 4th power, 
according to the Hagen–Poiseuille equation[177]. Additional studies are needed to more 
fully understand the relationship between skin hydration and ISF collection.  
 The cause of increased tissue hydration may be associated with an inflammatory 
response caused by minor tissue injury from repeated MN insertion into skin. In addition 
to edema, we observed a mild, highly localized erythema at the MN insertion site.  
Although inflammatory cells were not seen in skin histological sections collected 
immediately after MN patch treatment, it may have been too early to see inflammatory 
cells and examination of skin at later times would address this question. The mechanism 
of increased tissue hydration requires additional study.   
 
5.4.4 Limitations of this study 
There are limitations to this study in terms of the scope of the study and the ISF collection 
method itself. For example, this study used pig skin ex vivo and rat skin in vivo, which 
may not be fully predictive of results in human skin. This study also did not formally 
address the issue of safety other than acute effects at the time of ISF collection. However, 
we have used the same rats for many studies, especially during protocol development, and 
found that repeated collection of ISF using MN patches was well tolerated (data not 
shown). This study did not address the possibility of pain caused by ISF collection. While 
 
 
similar MN patches applied to the skin of human subjects were reported as painless[132], 
multiple MN punctures of skin has not been studied. In terms of the ISF collection method 
itself, it is simple to perform but nonetheless requires ~1 min of active interaction with the 
patient. Also, the ISF partially or completely dries in the paper reservoir, which 
complicates determination of absolute biomarker concentrations, although this type of 
approach is used in dried blood spot tests in current clinical practice[178].  
 
5.5 Conclusions 
This study presents the development of a minimally invasive, rapid, simple-to-use and 
cost-effective MN patch to harvest >2 µl of ISF within 1 min. The technique represents a 
significant improvement over current ISF collection methods that cause significant skin 
trauma, are time consuming and require expert personnel and equipment to perform. The 
optimized MN patch was prepared by adhering a thin strip of filter paper serving as a 
reservoir to a stainless steel MN array prepared by lithographically defined chemical 
etching. Factors such as water absorptiveness of the paper, number of skin insertions, 
number of MNs per patch, thickness of the MNs and wettability of the MN surface all 
increased the amount of ISF collected in pig skin ex vivo. ISF collection was similar in 
rat skin in vivo skin, where skin pre-treatment with microneedles 5 min prior to ISF 
collection resulted in a marked increase in ISF collection, which was associated with 
increased skin hydration. This technique can simplify access to biomarkers in ISF for 
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CHAPTER 6. MONITORING DRUG PHARMACOKINETICS AND 
IMMUNOLOGIC BIOMARKERS IN DERMAL INTERSTITIAL FLUID USING 
A MICRONEEDLE PATCH 
6.1 Introduction 
Rapid disease detection and treatment depend on identification and reliable measurement 
of biomarkers [179]. Blood is the most common clinical sample for diagnostic assays [180]. 
However, limitations of blood sampling include the need for expert training to collect blood 
by venipuncture, especially in neonates, infants and patients with fragile veins; difficulty 
of continuous monitoring due to blood clotting; and apprehension by patients associated 
with blood draws [181]. Blood also requires downstream processing for most diagnostic 
assays to remove red blood cells [154].  
 Other body fluids such as saliva and urine are more easily accessible [182] but have 
limited biomarkers of variable concentrations [183]. Interstitial fluid (ISF) is a body fluid 
that fills the space between cells in tissues and constitutes 75% of extracellular fluid and 
15-25% of body weight [158]. Recent studies have shown that ISF contains systemic 
biomarkers, but also contains other biomarkers that are unique or at much higher 
concentration compared to serum or plasma [6,7,121,157,158,159]. ISF is a clear fluid 
without red blood cells and does not clot, thus enabling simplified preparation for 
biochemical analysis.  
 ISF has been used for continuous glucose monitoring [184], analysis of tumor 
microenvironment [185] and bioavailability of topical drugs [186]. ISF has been sampled 
 
 
by techniques such as reverse iontophoresis [98], which requires frequent calibration and 
is limited to small molecules; suction blister [171], which requires specialized equipment 
and causes lasting skin damage; and microdialysis [92], which requires minor surgery and 
expert personnel; microporation of upper non-viable layer of skin using a focused NIR 
laser followed by ISF collection under vacuum[187] which collects up to 10 µl of ISF in 1 
hour .  
 More recently, microneedle (MN) technology has been developed for ISF 
sampling. MNs are micron-scale, sharp-tipped projections that can puncture micropores 
into the skin to access dermal ISF in a minimally invasive manner [29]. MN patches were 
developed initially for delivery of vaccines and drugs, where they have been shown to be 
painless, well-tolerated, easy-to-use and effective for delivering therapeutic molecules into 
skin [162,188]. MNs have also been used for detection of glucose and other biomarkers in 
dermal ISF [6,160].  
 Approaches to ISF collection using MNs include extracting ISF from skin through 
micropores for extracorporeal analysis [121], which typically takes 15 min or longer; 
swelling hydrogel-forming MNs with ISF in skin [118,120], which generally collects 
nanoliter quantities of ISF, which is insufficient for many biomarker assays; selectively 
binding biomarkers to MN surfaces modified for in-situ capture of biomarkers [8,115], 
which must be custom designed for each biomarker; and incorporation of sensors into MNs 
for in situ analysis of ISF [106,108,109], which is technically challenging and requires a 
different sensor for each biomarker.  
 
 
 To overcome the various limitations of prior MN technology, we developed a MN 
patch that collects microliters of ISF within one minute that can be assayed for any 
biomarker of interest. We used this MN patch to sample ISF, determine ISF concentrations 
of a model drug (vancomycin) and a model immunomarker (anti-polio antibodies), and 
compare them to serum concentrations. We chose vancomycin, an antibiotic commonly 
used to treat gram-positive methicillin-resistant Staphylococcus aureus infections 
(MRSA), because it’s very narrow therapeutic index requires therapeutic drug monitoring 
to ensure efficacy and minimize toxicity during patient care [122,189]. We chose to 
monitor anti-polio antibodies because they can be measured using well-established 
immunoassays by our collaborators at the WHO Global Specialized Reference laboratory 
located at the Centers for Disease Control and Prevention (CDC).  
 
6.2  Materials and methods 
6.2.1 Materials 
Monovalent, bulk inactivated polio vaccine (IPV) (Mahoney strain of type 1, Middle East 
Forces (MEF) strain of type 2 and Saukett strain of type 3) was kindly provided by 
Bilthoven Biologicals (Bilthoven, Netherlands). The antigen concentrations were 1675, 
963 and 950 D-antigen units (DU)/ml for IPV types 1, 2 and 3, respectively, determined 
by antigen-capture sandwich enzyme-linked immunosorbent (ELISA), as previously 
described [42]. 
 Vancomycin hydrochloride from Streptomyces Orientalis was purchased from 
Sigma Aldrich (St. Louis, MO). HPLC-MS grade acetonitrile, methanol and water were 
 
 
purchased from MedSupply Partners (Atlanta, GA) and formic acid (98%, ACS grade) was 
obtained from EMD Millipore Chemicals (Darmstadt, Germany). 
 
6.2.2 Microneedle patch fabrication 
MN patch dimensions were drafted using AutoCAD software (Autodesk, Cupertino, CA) 
to prepare patches by lithographically defined chemical etching (Tech Etch, Plymouth, 
MA). Patches were comprised of 9 MNs (650 µm long) each measuring 50 µm x 150 µm 
in cross section at the base and tapering to a tip of <1 µm radius of curvature.  
 Whatman grade 1 filter paper (Sigma Aldrich, St. Louis, MO) was cut into 
rectangular strips of desired dimensions (2 mm x 7 mm) using a CO2 laser (New Hermes 
Gravograph Model LS500XL, Gravotech, Duluth, GA). The patterns were made using a 
vector cut at 24 W power and a speed of 8 mm/s. To prevent burning due to excessive 
temperature rise during laser cutting, the heat capacity of the filter paper was increased by 
attaching it to an adhesive backing (3M, Maplewood, MN), followed by soaking in DI 
water until completely wet.  
 The final MN patch was prepared by adhering the paper strips to both sides of the 
base substrate of each MN patch to create a reservoir to collect ISF that flowed out of the 
skin during MN insertion. 
 
6.2.3 ISF collection procedure 
 
 
The MN patch was applied to rat skin up to 12 times while pinching the skin with a force 
of 20-40 N. The amount of ISF collected was estimated to be 4 µl once the 2 mm x 7 mm 
filter paper on both sides of the MN patch were saturated with ISF. This estimate was 
performed by determining sodium ion content in the MN patch paper backing using a 
sodium ion sensitive electrode (perfectION comb NA, Mettler Toledo, Columbus, OH). 
The sodium ion content measured in the samples was divided by the physiological sodium 
ion concentration in rat ISF of 143 mEq/L[165][165] to determine ISF volume collected. 
This method relies on the expectation that sodium ion concentration is constant in the ISF 
of normal rats [166]. 
 
6.2.4 Vancomycin pharmacokinetic study 
Procedures were performed on six Wistar rats (10-20 weeks old, female, Charles River 
Laboratories, Wilmington, MA) anesthetized by inhalation of isoflurane (AErrane, Baxter 
Healthcare, Deerfield, IL) in 100% oxygen during drug administration and sample 
collection. To administer vancomycin and collect blood, a silicone rubber tube was placed 
in the right jugular vein and kept locked with sodium heparin solution in physiological 
saline (100 U/ml). Care was taken to avoid administration of air bubbles, and blood 
samples were replaced with an approximately equal volume of heparinized saline to 
maintain blood volume. A 0.75 mg/ml solution of vancomycin hydrochloride in 0.9% NaCl 
injection solution (Hospira, Lake Forest, IL) was prepared and each rat was administered 
1 mg/kg dose via the jugular vein tube. Blood samples were obtained from the jugular tube 
before and 10, 20, 30, 45, 60 and 90 min after vancomycin administration. Companion ISF 
 
 
samples were also collected at the same time points. At the end of the study, the rats were 
euthanized by carbon dioxide gas asphyxiation. These experiments were approved by the 
Georgia Institute of Technology Institutional Animal Care and Use Committee.  
 
6.2.5 Extraction of vancomycin from ISF/serum samples 
The extraction of vancomycin from ISF and serum samples was performed according to a 
previously reported method [189]. Serum samples were diluted by mixing 4 µl of serum 
in 100 µl of deionized water. ISF was extracted from MN patches by centrifuging 1 MN 
patch in 100 µl of deionized water at 6000 x g for 10 min. All samples were stored at 4 
°C until testing. Then, 100 µL of formic acid/methanol (1:1, v/v) was added to each ISF 
or serum sample. The mixture was vortexed for 30 s and then centrifuged for 15 min at 
12,000 x g. The supernatant was removed, diluted with 300 µL of high-performance 
liquid chromatography – mass spectrometry (HPLC-MS) grade water, and then 
transferred to an HPLC vial for HPLC-MS/MS analysis. 
 
6.2.6 HPLC-MS/MS analysis 
Calibrators were prepared by adding aliquots of vancomycin stock solution to a drug-free 
serum matrix to create the following concentrations: 1.0, 2.0, 6.0, 13, 32 and 75 µg/mL. 
The calibration curve was plotted using Mass Hunter QQQ Quantitative Analysis software 
(Agilent, Santa Clara, CA). The data were weighted 1/x and concentrations of vancomycin 
were calculated by the software. 
 
 
 Chromatography was performed by injecting 50 μl of extracted calibrator or sample 
onto an Agilent 1200 series HPLC fitted with an Agilent ZORBAX Eclipse C18 column 
(2.1 x 150 mm, 3.5 µm particle size). The column temperature was maintained at 35°C and 
the flow rate was maintained at 0.4 mL/min. Mobile phase A consisted of 0.25% formic 
acid in water and mobile phase B consisted of 0.25% formic acid in acetonitrile. 
Vancomycin was separated using a gradient method as follows: 5.0% mobile phase B from 
0.00-3.00 min, increased to 30% mobile phase B from 3.01-10.00 min, increased to 90% 
mobile phase B from 10.01-12.00 min, decreased to 5.0% mobile phase B from 12.01-
14.00 min, then maintained at 5.0% mobile phase B from 14.01-16.00 min.  
 An Agilent 6410 triple quadrupole mass spectrometer was used to analyze samples 
in positive ion mode. The mass spectrometer parameters were as follows: capillary voltage 
of 3500 V, electron multiplier voltage at 300 V, gas temperature of 350 °C, nebulizer 
pressure of 240 kPa and gas flow rate of 10 L/min. Vancomycin was monitored using 
multiple reaction monitoring of the transition m/z 725.6→144.2. Chromatographic peaks 
were then manually integrated and analyzed using MassHunter software (Agilent, Santa 
Clara, CA).  
 
6.2.7 Polio immunization  
Six Wistar rats (10-20 weeks old, female, Charles River Laboratories) were anesthetized 
by isoflurane (AErrane, Baxter Healthcare) inhalation during all procedures. IPV stock 
solutions were combined and diluted using medium 199 to a concentration of 44, 8 and 
36 DUs of IPV types 1, 2 and 3, respectively in 100 µl, as determined by ELISA. We 
 
 
administered two 100 µl intramuscular injections per rat (one in each hind limb) for a 
total dose of 88, 16 and 72 DU of IPV types 1, 2 and 3, respectively.  
 Sera and ISF samples for polio-specific IgG testing were collected before and 1, 3 
and 4 weeks after immunization. Twelve weeks after the initial vaccination, all animals 
were given a second dose of trivalent IPV in the same manner as the first dose. Sera and 
ISF samples for neutralizing antibody titer assay were collected before and 1, and 2 
weeks after the second dose. 
 Blood samples (≤ 500 µl) were collected in microtainer collection tubes with clot 
activator (BD Diagnostics, Franklin Lakes, NJ) by tail bleeding after making a small 
incision in the tail using a surgical blade. ISF samples were collected from the lateral side 
of the rat after hair removal using electric shears followed by application of depilatory 
cream (Nair, Princeton, NJ). Hair removal was performed at least 1 day prior to ISF 
collection to avoid possible ISF contamination by the depilatory cream. At the end of the 
study, the rats were euthanized by carbon dioxide gas asphyxiation. These experiments 
have been approved by the Georgia Institute of Technology Institutional Animal Care and 
Use Committee.  
 Serum was separated by centrifuging the blood samples at 6000 x g for 1.5 min in 
an Eppendorf Centrifuge 5415R (Eppendorf AG, Hamburg, Germany). For the anti-polio 
IgG testing, 6 µl of serum was diluted with 120 µl of dilution buffer (provided with the 
ELISA kit) and the MN patch containing 4 µl of ISF was placed in an Eppendorf tube 
containing 80 µl of dilution buffer and centrifuged at 6000 x g for 1.5 min.  
 For polio-specific neutralizing antibody titers, a 1:16 dilution of serum samples was 
performed by mixing 16 µl of serum with 240 µl of Dulbecco’smodified Eagle Medium 
 
 
(DMEM, Gibco, Grand Island, NY) and 2% fetal bovine serum (FBS, Gibco) and a 1:16 
dilution of ISF samples was performed by extracting ISF from the MN patches by 
centrifuging in DMEM (2 MN patches per 120 µl) at 6000 x g for 1.5 min. The undiluted 
serum samples and the diluted ISF/serum samples were stored in Eppendorf tubes at -20 
°C until used.  
 
6.2.7.1 Anti-polio IgG measurements and polio-specific neutralizing antibody titers 
A commercially available ELISA IgG assay (Anti-Polio viruses 1-3 IgG ELISA kit, Alpha 
Diagnostics Intl, San Antonio, TX) was used for the detection and quantitative 
determination of IgG antibodies to polio virus in serum and ISF specimens. Prior to testing, 
the sera and ISF samples were thawed and diluted to 1:100 by adding 480 µl and 320 µl, 
respectively, of low Nsb diluent (provided with the ELISA kit). 
 Neutralizing antibody titers to poliomyelitis were measured from collected sera and 
ISF samples at the WHO Global Specialized Reference laboratory at CDC (Atlanta, GA) 
using methods previously described [190]. Briefly, 80-100 CCID50 of Sabin strains 1, 2, 
and 3 poliovirus and two-fold serial dilutions of serum and ISF (starting at 1:4) were 
combined and incubated for 3 h at 35 °C prior to addition of HEp-2(C) cells. The plates 
were stained with crystal violet and cell viability was measured by optical density after 5 
days of incubation at 35 °C and 5% CO2. Each sample was run in triplicate. The 
neutralization titers were estimated by the Spearman-Karber method [191] and reported as 
the reciprocal of the calculated endpoint. The limit of detection for this assay is a 2.5 log2 
titer, and the precision of detection is ± 0.5 log2 titer.  
 
 
6.2.8 Statistical analysis 
Statistics were calculated using either Prism software version 7.0 (Graphpad, La Jolla, CA) 
or Excel (Microsoft, Redmond, WA). Arithmetic mean and median values of the samples 
are reported. Comparison between three or more samples was performed by one-way 
ANOVA or two-way ANOVA. Correlation between data was determined by Pearson’s 




6.3.1 ISF collection by microneedle patch 
The MN patch comprised of a two-component system: 2 strips of filter paper (to create a 
reservoir for ISF) on both sides of the backing of a stainless steel MN array (which 
punctures the skin to create micropores for ISF to flow out of the skin) (Figure 6-1A). The 
ISF collection was performed by repeatedly inserting the MN patch to the skin surface with 
a force of 20-40 N, thereby inducing flow of ISF out of the skin and into the paper 





Figure 6-1: Collection of ISF using a microneedle (MN) patch. A) Representative 
photographic image of a MN patch showing a row of nine MNs measuring 650 µm in 
length extending from a patch backing with rectangular strips of filter paper adhered 
to both sides. B) Representative photographic image of ISF collection from hairless 
rat skin in vivo. Upon application of the MN patch to the skin, clear interstitial fluid 
(ISF) flowed out of the skin through micropores created by the MNs and was collected 
in the paper reservoirs. The paper reservoir shown in this image is mostly wetted by 
ISF, with only the upper left corner still dry, as indicated by different visual 
appearance. C) Representative photographic image of a MN patch after ISF 
collection by repeated application to skin. The amount of ISF collected on each strip 
of paper was ~2 µl, for a total of ~4 µl per MN patch. 
                                                                                              
6.3.2 Vancomycin pharmacokinetics 
To assess the utility of ISF collection by MN patch, we studied the pharmacokinetics of 
vancomycin in ISF compared to serum of rats. For both ISF and serum, vancomycin 
concentration was rapidly increased by the first measurement made 10 min after bolus 
injection of vancomycin as shown in Figure 6-2A and B.  
After reaching a peak, the vancomycin concentration decayed, which followed the 
expected pharmacokinetic curve for this drug [192]. Plotting paired individual ISF and 
serum drug levels yielded a roughly linear correlation with a slope of 0.75 ± 0.06 (R2 = 
0.40), indicating a generally higher vancomycin concentration in ISF compared to serum. 
 
 
 A one-way ANOVA analysis of the pharmacokinetic profiles of each rat showed 
no statistically significant difference between ISF and serum concentrations (p ≥ 0.15) 
Pharmacokinetic analysis showed that the average peak vancomycin concentration (Cmax) 
and area under the curve (AUC) were not significantly different in ISF and serum 
(Student’s t-test, p > 0.8). A ~17 min delay in time to peak vancomycin concentration (Tmax) 
in ISF compared to serum was statistically significant (Student’s t-test, p < 0.05). This is 
consistent with prior literature, which reported correlation of vancomycin levels in ISF and 
blood and a delayed time for equilibration of vancomycin levels between ISF and blood 
[123,189].  
 In this study, each rat had ISF collected seven times over the course of 90 min (i.e., 
a total of 42 ISF collections among the six rats in the study). Each ISF collection was done 
at a different skin site. These ISF collection procedures involving insertion of MNs into the 
skin up to 12 times each were well tolerated, with only very mild erythema and edema seen 
at the site of ISF collection. There were no other notable effects of the ISF collection 
procedure on the animals.  
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Figure 6-2: Pharmacokinetics of vancomycin in rat ISF and serum. A) 
Pharmacokinetic profile of vancomycin concentration in ISF and serum samples 
collected from rats administered a 1 mg/kg bolus intravenous injection of 
vancomycin. Data points show mean ± standard deviation (SD) (n = 6 rats). B) 
Correlation between vancomycin concentration in paired serum and ISF samples 
(r= 0.61, p<0.005, Pearson’s correlation coefficient test). Dashed lines represent ± 30 
% of the slope of the linear regression line (shown as solid black line), which are 
included as a visual guide. Data are the same as shown in (A)  
Table 6-1: Comparison of AUC, Cmax and Tmax values of vancomycin 
pharmacokinetics between ISF and serum 
Pharmacokinetic 
parameter1 
ISF Serum Ratio 
(ISF:serum) 
AUC (µg.min/ml) 138 ± 43 106 ± 25 1.3 ± 0.2 
Cmax (µg/ml) 2.5 ± 1
 2.6 ± 0.6 0.9 ± 0.2 
Tmax (min) 26.6 ± 16
* 10 ± 0 2.7 ± 1.6 
 
 
1Data are presented as mean ± SD (n= 6 rats).  AUC, area under the concentration-time 
curve. Cmax, maximum concentration. Tmax, time required to reach maximum concentration. 
Asterix (*) denotes parameters with statistically significant difference (p < 0.05) between 
ISF and the companion serum value. 
6.3.3 Immune responses to inactivated polio vaccination 
6.3.3.1 Anti-polio IgG responses 
We also assessed the utility of ISF collection by MN patch in detection of anti-polio IgG 
responses in rats immunized with trivalent inactivated polio vaccine. Anti-polio IgG titers 
were negligible before and one week after vaccination. Three and four weeks after 
vaccination, IgG titer in both ISF and serum increased dramatically, but titers in ISF were 
~23% lower than in serum (Student’s t-test, p < 0.03). Plotting paired individual ISF and 
serum IgG titers yielded a linear correlation with a slope of 1.27 ± 0.09 (R2 = 0.81), 
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Figure 6-3: Anti-polio IgG responses to inactivated polio vaccination in rats. a) Anti-
polio IgG titers determined by ELISA in ISF and serum samples collected before and 
1, 3 and 4 weeks after vaccination with trivalent IPV by intramuscular injection. Each 
data point represents a single animal while the bars represents the median values of 
each group (n = 6 rats). Asterisk (*) represents a significant difference (Student’s t-
test, p < 0.03). b) Correlation between anti-polio IgG titers in paired serum and ISF 
samples (r = 0.90, p<0.005, Pearson’s correlation coefficient test). Dotted lines 
represent ± 30% of the slope of the linear regression line (shown as solid black line), 
which are included as a visual guide. Data are the same as shown in (a)  
 
6.3.3.2 Polio-specific neutralizing antibody responses 
After observing the anti-polio IgG response in ISF, we performed a follow-up study to 
detect polio-specific neutralizing antibody responses by collecting ISF and companion 
blood samples after vaccinating the rats with a booster dose of trivalent inactivated polio 
vaccine. Before vaccination, neutralizing antibody titers in ISF and serum samples for all 
three serotypes were below the limit of detection (Figure 4a). One and two weeks after 
vaccination, neutralizing antibody titers increased in both ISF and serum, but titers in ISF 
were ~30% lower than in serum (Student’s t-test, p<0.01). This rapid increase of titer 
within one week is expected because responses to booster vaccination are typically seen 
on this time scale [27]. Paired individual ISF and serum titers were linearly correlated with 
 
 
a slope of 1.36 ± 0.07 (R2 = 0.79), 1.41 ± 0.06 (R2 = 0.78) and 1.36 ± 0.06 (R2 = 0.82) for 
IPV types 1, 2 and 3, respectively, indicating a generally lower neutralizing antibody titer 
in ISF compared to serum. 
 These were the same rats that were used in the study of polio-specific IgG, meaning 
that each rat had ISF collected seven times over the course of 14 weeks. The procedures 
were well tolerated, with only very mild, transient erythema and edema seen at the site of 
ISF collection. 
 
Figure 6-4: Neutralizing antibody responses to inactivated polio vaccination. 
Neutralizing antibody titers to a) IPV type 1, b) IPV type 2 and c) IPV type 3 in ISF 
and serum samples collected before and 1 and 2 weeks after administration of a 
booster dose of trivalent IPV by intramuscular injection in rats (the first dose was 
administered 12 weeks earlier). The limit of detection for the assay was 2.5 log2. Each 
data point represents a single animal while the bars represents the median values of 
each group (n = 6 rats). Asterisk (*) represents a significant difference (Student’s t-
test, p < 0.01). Correlation between neutralizing antibody titers in paired serum and 
ISF samples for d) IPV type 1, (r= 0.89, p<0.005, Pearson’s correlation coefficient 
test), e) IPV type 2 (r= 0.87, p<0.005) and f) IPV type 3 (r= 0.91, p<0.005). Dotted lines 
 
 
represent ± 30% of the slope of the linear regression line (shown as solid black line), 
which are included as a visual guide. Data are the same as shown in (a) 
 
6.4 Discussion 
6.4.1 MN patch for simplified ISF sampling 
 ISF is a relatively unexplored body fluid in major part due to lack of simple, reliable 
techniques to sample this fluid. In this study, we used a simple MN patch-based method to 
collect microliters of ISF in a minimally invasive manner within one minute. The MN patch 
consists of a steel MN array with strips of filter paper adhered on both sides of the patch 
backing. The MN patch should be inexpensive and the manufacturing process should be 
straightforward. ISF collection can be performed without expert training and the amount 
of ISF sampled can be controlled by changing the number of insertions into skin and the 
size/type of paper used for the ISF reservoir. We have performed repeated ISF collection 
on the same rats during these studies (i.e., ISF was collected a total of 84 times among 12 
rats) and found that the procedure was well tolerated with a mild, localized erythema at the 
MN insertion site which resolved within one day (data not shown). 
 
6.4.2 Drug monitoring in ISF 
While other body fluids such as saliva and urine have been investigated for therapeutic 
drug monitoring [182], ISF is a body fluid of increasing interest as a source of biomarkers 
providing dermal and systemic physiological information, as well as drug 
pharmacokinetics. Most research has been focused on detection of glucose in ISF, and 
 
 
indwelling subcutaneous sensors are now commonly used to continuously measure glucose 
concentration in subcutaneous ISF as a surrogate for blood glucose levels in diabetic 
patients [100].  
Other biomarkers have also been investigated in ISF, largely for research purposes. A 
comprehensive review of 87 individual pharmacokinetics comparisons of various classes 
of antibiotics demonstrated different ratios of drug concentration in ISF versus plasma, 
which was largely explained by different degrees of protein binding [123]. Other drugs 
such as scopolamine, theophylline, methotrexate, vancomycin, carbamazepine and 
phenobarbital have also been measured in ISF and had similar AUC in serum/plasma and 
ISF samples [124,126]. On the other hand, some drugs such as phenytoin were not 
detectable in ISF [126]. These studies involved ISF collection using microdialysis and 
ultrafiltration probes, which cause significant skin damage, are time consuming to perform, 
require expert personnel and specialized equipment, and are not suitable for routine clinical 
use.  
 We demonstrated the ability of a minimally invasive MN patch to quickly collect 
ISF and detect biomarkers of interest, which provides an alternative approach to therapeutic 
drug monitoring in ISF. We collected microliters of ISF within 1 min, which should be 
sufficient to run many assays to detect biomarkers of clinical significance [172,193]. This 
contrasts with other MN-based methods that typically sample nanoliters of ISF and/or 
require as long as an hour of collecting [118,121]. In this study, pharmacokinetics of 
vancomycin showed similar AUC and Cmax values in ISF and serum samples in rats, 
although vancomycin concentrations overall were slightly higher on average compared to 
serum levels. A delay in Tmax was observed in ISF, which is consistent with literature 
 
 
[123,189]. More studies are needed to understand the factors that influence drug 
distribution between ISF and blood. For example, vancomycin was shown to distribute into 
ISF at levels similar to serum in healthy patients with limb infections [194], but had wide 
variability in vancomycin penetration into ISF in diabetic patients [195].  
 
6.4.3 Immunodiagnostic markers in ISF 
We also used ISF collected by MN patch to detect polio-specific IgG and neutralizing 
antibodies, which were at similar concentrations in ISF and plasma, although ISF levels 
were slightly lower. It has been shown that skin vaccination, especially by MN patch, can 
provide stronger, broader, longer-lasting and otherwise improved humoral and cellular 
immune responses compared to intramuscular injection [196]. Likewise, skin-associated B 
cells are believed to play an important role in skin immunity and inflammation [197] . 
Therefore, the ability to measure local antibody titers in tissue ISF could play an important 




We studied ISF collected from the skin using a minimally invasive, simple-to-use, low-
cost MN patch that can collect microliters of ISF within 1 min. Of interest to therapeutic 
drug monitoring, we performed a pharmacokinetic study of vancomycin in rats and found 
that AUC and Cmax were similar in ISF, but Tmax was delayed in ISF by ~17 min compared 
to serum. Another study examined immunologic biomarkers in ISF by administering 
 
 
inactivated polio vaccine to rats and determined that polio-specific IgG and neutralizing 
antibody titers were similar in ISF and companion serum samples. We conclude that ISF 
collection using a novel MN patch can provide simple and rapid collection of microliters 
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CHAPTER 7. CONCLUSIONS 
7.1 Dissolving MN patch for polio vaccination 
Poliomyelitis is a highly infectious disease which can only be prevented by immunization. 
The aim of this study was to develop a thermostable dissolving MN patch for polio 
vaccination. The formulation optimization studies involved screening of different 
excipients, buffers and pH conditions for the 1st and 2nd cast of the MN patch.  The four 
best excipients found from primary screening were D-sorbitol, maltodextrin, sucrose and 
trehalose. Further optimization of the ratios of these excipients resulted in a final MN patch 
with a first cast of IPV mixed with D-sorbitol and maltodextrin, and a second cast 
containing fish gelatin and D-sorbitol in histidine buffer. 
Process optimization studies based on the ELISA showed the air drying at 25°C with 
desiccant for 2 days resulted in minimal loss of IPV and subsequent lyophilization did not 
show any significant advantage. Drying at elevated temperatures resulted in reduction in 
IPV potency. Using TGA, we found that the residual moisture content (RMC) in the MN 
patches was initially 6.5 % which continued to drop down to 1.2 % depending on storage 
conditions. However, the moisture content did not correlate with the IPV activity, implying 
that further removal of bound and unbound water did not influence the thermal stability. In 
contrast, IPV activity and temperature were correlated. This shows that IPV destabilization 
processes are significantly driven by elevated temperature over the range of conditions 
studied. 
The final optimized MN patch was deemed to be sufficiently mechanically robust based 
 
 
on successful insertion in ex-vivo pig skin. Examination of used microneedle patch after 
15 min showed complete dissolution of the microneedles. 
The optimized MN patch maintained  >70% activity of all three serotypes after 2 months 
and >50% activity after 1 year storage at 5°C or 25°C with desiccant.  Storage at 40°C 
yielded >40% activity after 2 months and >20% activity after 1 year. In contrast, IPV 
completely lost its potency if dried without any excipients, and commercial liquid IPV 
showed <10% activity after 1 month of storage at 40 °C and is recommended to be stored 
at 2°C to 8°C.  
Using DSC, we found that the MN matrix initially had a Tg of 48 °C, which increased over 
time to as much as 59 °C depending on storage condition. This increase in Tg is consistent 
with the observed decrease in RMC with storage time because water is a potential 
plasticizer, and loss of moisture from MN matrix during storage would result in increase 
in Tg. since water acts as a plasticizer. The observed thermal stability at 5 °C and 25 °C 
may be because they are well below the Tg, but stability was worse at 40 °C, which is closer 
to the Tg of the MNs. Fourier-transform infrared spectra of samples after storage for 30 
days at 5 °C, 25 °C or 40 °C appeared very similar, which means that no significant 
chemical changes were detected among the samples. Structural changes in MN patches 
measured by X-ray diffraction showed a decrease in crystalline phase and an increase in 
amorphous phase with storage. This finding is consistent with the observed increase in Tg 
and decrease in RMC. Studies aimed at understanding this stabilization mechanism have 
shown that sorbitol is preferentially excluded from the surface of the native protein, i.e. in 
the presence of sorbitol, proteins are preferentially hydrated. This preferential hydration 
induces protein stabilization[198]. It is theorized that polyols such as sorbitol stabilize IPV 
 
 
based on a preferential exclusion effect. Elevated temperatures may be affecting these 
microscopic interactions between sorbitol and IPV there by resulting in destabilization. 
7.2 Paper based MN patch for ISF sampling and detection of biomarkers 
Measurement of biomarkers in body fluids is a valuable tool for accurate disease diagnosis 
and monitoring. In addition to body fluids such as blood, urine, saliva, sweat, and tears, 
ISF is a rich source of biomarkers for diagnostic applications. Development of simple-to-
use point-of-care (POC) devices is highly desirable due to the need for regular or 
continuous monitoring of analytes, and the need to non-invasively sample biomarkers has 
opened the potential for ISF as an alternate body fluid.  
Current methods like suction blister, microdialysis, sensor implantation and open flow 
microperfusion cause significant skin trauma resulting in long healing times, require expert 
personnel and are time consuming. Other non-invasive methods such as reverse 
iontophoresis are limited by the inability to sample large molecules. MNs have been 
demonstrated as a minimally invasive technique for ISF collection. Previous studies for 
ISF collection using MNs have been limited by the sub-microliter volumes of ISF which 
are not sufficient for multiple analyte measurement and often require 15-20 min time for 
collection.  
The second half of the thesis was focused on development of a minimally invasive, rapid, 
simple-to-use and cost-effective method to collect ISF from the skin involving a 
microneedle (MN) patch.  
 
 
The patch consists of a simple two component system: A steel MN array to penetrate the 
skin and form micro-channels for ISF to flow out of the skin and a thin strip of filter paper 
to create a reservoir for ISF. 
We identified different parameters which influenced the ISF collection and found an 
increase in the ISF collected by increasing the number of skin insertions, MN thickness 
and increasing number of MNs. Increasing number of skin insertions and number of MNs 
per patch both should increase the number of micropores for ISF to flow out of skin. 
Thicker microneedles should result in larger micropores, thereby allowing easier access to 
ISF. We also found that improving the wettability of steel MN surface resulted in faster 
ISF collection by facilitating ISF flow to the paper reservoir. 
An interesting finding was that MN patch pre-treatment of the skin followed by a 5 min 
wait time dramatically increased ISF collection by 4 times. The effect involved an increase 
in skin hydration of more than 20% which can be associated with increased rates of ISF 
collection. In addition to edema, we observed a mild, highly localized erythema at the MN 
insertion site which resolved within a day.   
We then, tested the utility of this optimized MN patch by demonstrating the suitability of 
using ISF for therapeutic drug monitoring (TDM). We performed rat in-vivo studies and 
showed similar vancomycin concentration-time profiles and pharmacokinetic parameters 
in the ISF and blood. We also, for the first time, detected polio specific neutralizing 
antibodies, and anti-polio IgG in ISF similar to blood in rats immunized with polio vaccine. 




CHAPTER 8. FUTURE DIRECTIONS 
8.1 MN patch with faster dissolution kinetics, shorter wear time with 
biocompatible excipients 
Even though the optimized dissolving MN patch was thermostable, and mechanically 
robust, the dissolution time was ~ 15 minutes. This patch will be used in a pediatric 
population which is challenging, partially due to the age ranges within this population. 
Studies have shown a strong consensus regarding MN technology in children[199], 
however, it would be highly desirable to have a MN patch with faster dissolution in the 
order of 1-2 minutes for a shorter wear time. Another approach could be to design an MN 
patch with separable MNs for shorter administration time[40]. 
Fish gelatin is one of the components of the MN patch and there is a risk related with 
allergic reactions and sensitization. Future studies may focus on other more biocompatible 
biopolymer IPV stabilizers.  
The studies performed showed that the dissolving MN patch maintained >70% activity 
after 2 months and >50% activity after 1 year at 5°C or 25°C, but maintained >40% activity 
after 2 months and >20% activity after 1 year at 40 °C.  It would be desirable to have an 
MN patch which is more stable at elevated temperatures. A more complete screen of 
various excipients could be performed which may result in formulations with an even 
higher level of stabilizing activity especially at elevated temperature. Due to temperature 
fluctuations between night and day, the MN patches may not need to maintain activity at 
elevated temperatures for an extended period of time. Transient temperature stability may 
 
 
be sufficient. While MN patches were tested for IPV activity after storage, they were not 
tested for mechanical robustness. Mechanical testing must be performed after extended 
storage to ensure that the microneedle patches remain sharp and retain the ability to easily 
insert into the skin.  
The immunogenicity of this optimized MN patch was not tested in animal models which 
has to be addressed in the future. 
 
8.2 Microneedle patch for ISF collection 
The optimized MN patch was demonstrated to be capable of collecting >2 µl of ISF within 
a minute upon repeated skin insertions in rats. We also demonstrated that multiple 
microliters of ISF can be collected by MN skin pre-treatment followed by a 5 min delay. 
Nevertheless, the method involves repeated MN insertions and its effect on skin tolerability 
and the possible pain has not been studied in detail, especially in humans. This study was 
performed in pig skin ex vivo and rat skin in vivo only. Human feasibility studies should 
be performed in the future to test the effect of MN skin pre-treatment on skin hydration. 
Future studies should also formally address the issue of safety and the possibility of pain 
caused by ISF collection.  
An important finding from this study was that the need to apply positive pressure and 
suction could be avoided by multiple MN insertions. The ISF collection was facilitated by 
the “pumping” action of multiple insertions which increases the number of pathways out 
of the skin. Since the rate-limiting step for ISF collection is often transport through the skin 
 
 
to the site of MN puncture, such that forces that generate convective flow in the skin can 
significantly facilitate ISF collection[121]. Future studies could test the minimum number 
of insertions required to cause the ISF recruitment. More mechanistic studies should be 
performed to understand time scales for ISF recruitment, effect of other factors such as age, 
ethnicity and hydration levels. 
Other studies may be focused on determining other less invasive methods for ISF 
recruitment without the need for multiple MN insertions.  
8.3 Microneedles for detection of biomarkers in ISF 
We demonstrated the utility of our MN patch in detection of vancomycin in ISF for TDM 
and detection of polio specific antibodies and anti-polio IgG. This MN technology could 
be used for detection of many other drugs and disease specific biomarkers. Some drugs 
may not partition well into ISF and future mechanistic studies should address intrinsic 
factors that influence the distribution in ISF. 
The filter paper used in our optimized MN patch acted as a reservoir for ISF. This involved 
additional processing steps for extraction of the biomarkers from the paper. Future studies 
should address improvement of the MN patch to develop an in-built detection system by 
methods such as functionalization of the paper using gold nanoparticles (GNP) or usage of 
paper based microfluidic device. GNPs possess distinct physical and chemical attributes 
which make them excellent choice for biosensors. GNPs are inert, they possess high 




GNPs could be functionalized with aptamers, or other peptides for targeted detection of 
potential biomarker and immobilized on the paper. Factors such as functionalization 
efficiency, concentration of GNP solution, amount of aggregation, and immobilization 
time will have to be tested to determine GNP loading onto the paper. The amount of 
biomarker collected could be quantified by using GNPs as signal amplification tags as in 
Surface Enhanced Raman Spectroscopy (SERS) or for localized surface plasmon 
resonance (LSPR) spectroscopy. 
The MN patch maybe attached to a paper-based microfluidic devices functionalized with 
reagents for colorimetric assays[200]. The color changes could be captured with a camera 
and the assay results could be quantified by comparing the intensities of the color 




CHAPTER 9. APPENDIX A. SUPPORTING INFORMATION FOR CHAPTER 4 
A.1.1 Excipient screening for IPV stabilization shown in Table A-1. 
Table A-1: Design of Experiments table showing excipient combinations tested for 
IPV stabilization1 
 
1The left column shows the formulation number and the other columns show the 






Figure A-1: Effect of stabilizing excipients on (A) IPV type 1 and (B) IPV type 2 
activity before drying, after air drying, after subsequent lyophilization and after 
storage. Vaccine was formulated with combinations of different excipients (each 
present at a concentration of 5% w/v) in 150 mM histidine buffer at pH 6.5 (see 
Table S1 for key to excipient formulations). In each set of bars, the first bar shows 
activity of liquid IPV formulated with excipients before drying. The second bar 
shows IPV activity after air drying at 5°C with desiccant overnight after casting 
onto PDMS chips. The third bar shows IPV activity after lyophilization. The fourth 
bar shows IPV activity after storage at 25 °C with desiccant for 1 week. The 
unformulated vaccine control data is shown as D6 bars on the far left. All IPV 
activity (determined by ELISA) is shown as percentage of concentrated stock 
vaccine solution. Asterisk (*) indicates combination excipient formulation which 
maintained >80% activity drying and storage. Data represent mean ± SEM 






























































Before Drying After air drying






































































Figure A-2: Effect of formulation buffer and pH on (A) IPV type 1 and (B) IPV type 
2 activity after air drying on PDMS chips, after subsequent lyophilization and after 
storage. IPV was formulated with 5% w/v maltodextrin and 5% w/v D-sorbitol in 
0.1 M buffer with pH adjusted using 1 N HCl or 1 N NaOH. Storage was carried out 
at 40 °C for 3 or 7 days with desiccant. KHP: Potassium hydrogen pthalate, M199: 
Medium 199. In each set of bars, IPV activity (determined by ELISA) is shown in 
the first bar after air drying at 5°C overnight and lyophilization, in the second bar 
after storage in a desiccator at 40 °C for 3 days and in the last bar after storage at 40 
°C in a desiccator for 1 week. Stability of unformulated IPV (i.e., without 
maltodextrin or D-sorbitol) in M199 media is shown in the bars on the far right.  
Hash (#) represents buffer which did not significantly affect IPV activity compared 
to activity in the vaccine casting solution (general linear model, p > 0.80). Asterisk 
(*) represents buffer which had the most adverse effect on IPV stability compared 
to activity in the vaccine casting solution (general linear model, p < 0.03). All IPV 
activity is shown as percentage of activity in the vaccine casting solution. Data 
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A.2 Optimization of IPV MN patches 
A.2.1 Optimization of 1st cast formulation 
 
Figure A-3:  Effect of 1st cast excipient ratio (maltodextrin to D-sorbitol) on (A) IPV 
type 1 and (B) IPV type 2 activity after fabricating MN patches, air drying, 
subsequent lyophilization and storage with desiccant at 40 °C for 2 days. Trivalent 
IPV was formulated with stabilizing excipients at a total concentration of 10 w/v% 
in the vaccine casting solution. The mass ratios used were MS80 (maltodextrin: D-
sorbitol 80:20), MS50 (maltodextrin: D-sorbitol 50:50) and MS20 (maltodextrin: D-
sorbitol 20:80). The 2nd cast polymer matrix solution consisted of 45 wt% fish 
gelatin to D-sorbitol (78:22) in 0.15 mM histidine buffer. All IPV activity 
(determined by ELISA) is shown as percentage of vaccine activity in the casting 
solution. In each set of bars, the first bar shows IPV activity in MN patch after air 
drying at 5°C in a desiccator for 2 days, the second bar shows IPV activity after 
additional lyophilization and the last bar shows the IPV activity after storage at 40 
°C for 1 week with desiccant. There was no significant difference between the 
different ratios of maltodextrin to D-sorbitol (Student’s t-test, p > 0.05). Data 

















































A.2.2 Optimization of second cast  
 
Figure A-4:  Effect of 2nd cast excipient ratio (fish gelatin to D-sorbitol) on (A) IPV 
type 1 and (B) IPV type 2 activity after fabricating MN patches, air drying, further 
lyophilization and storing with desiccant at 40 °C for 7 days. Trivalent IPV was 
formulated with 10 w/v% casting solution of maltodextrin: D-sorbitol (20:80) and a 
45 wt% 2nd cast solution consisting of varying mass ratios of fish gelatin to D-
sorbitol. GS88 (fish gelatin: D-sorbitol 88:11), GS78 (fish gelatin: D-sorbitol 78:22) 
and GS55 (fish gelatin: D-sorbitol 55:45) in 0.15 mM histidine buffer. All IPV 
activity (determined by ELISA) is expressed as a percentage of IPV activity in the 
vaccine casting solution. In each set of bars, the first bar shows IPV activity in MN 
patch after air drying followed by lyophilization and the second bar shows the IPV 
activity after storage at 40 °C for 1 week with desiccant. Asterisk (*) indicates a 
significant difference between the IPV activity compared to other samples 
(Student’s t test, p < 0.05). Data represent mean ± SEM (standard error of the 




















































A.3. Effect of drying conditions  
 
 
Figure A-5: Effect of air drying, subsequent lyophilization and storage conditions on 
(A) IPV type 1 and (B) IPV type 2 activity of MN patches air dried at 5 °C, 25 °C or 
40°C with desiccant. Trivalent IPV was formulated with 10 w/v% casting solution of 
maltodextrin: D-sorbitol (20:80) and a 45 wt% 2nd cast solution consisting of fish 
gelatin to D-sorbitol (78:22). All IPV activity (determined by ELISA) is expressed as 
a percentage of IPV activity in the vaccine casting solution. In each set of bars, the 
first bar shows IPV type 2 activity in MN patch after air drying, the second bar 
shows the activity after subsequent lyophilization, the third bar shows activity for 
MN patches storage at 40 °C for 1 week with desiccant (no lyophilization) and the 
last bar shows the activity for MN patches storage at 40 °C for 1 week with 
desiccant after lyophilization. Data represent mean ± SEM (standard error of the 
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A.4 Long term stability of polio MN patches 
 
Figure A-6: Effect of storage temperature on IPV types 1, 2 and 3 activities of 
commercially available vaccine, IPOL®  Sanofi Pasteur SA, Rockville, MD) stored 
with desiccant for up to 1 months at 40 °C. Data represent mean ± SEM (standard 
error of the mean) of n= 3 replicates.  
A.5 Correlation of residual moisture content in patch to IPV stability 
 
Figure A-7: Correlation of (A) IPV type 1 and (B) IPV type 2 activity in MN patches 
to RMC of the patches measured after storage at 5, 25 or 40 °C with desiccant or 
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an R2 value of 0.032 and 0.049 for IPV type 1 and IPV type 2, respectively. Data 
represent mean ± SEM (standard error of the mean) of n= 3 replicates.  







Figure A-8: Correlation of (A) IPV type 1 and (B) IPV type 2 (C) IPV type 3 activity 
in MN patches to storage temperature of 5, 25 or 40 °C with desiccant. Regression 
analysis showed an R2 value of 0.38, 0.39 and 0.67 for IPV type 1, IPV type 2, and 
IPV type 3 respectively. Data represent mean ± SEM (standard error of the mean) 























































A.7 XRD patterns for raw materials used for MN matrix patch preparation 
 
Figure A-9: Representative X-ray diffraction (XRD) patterns corresponding to fish 
gelatin, maltodextrin and D-sorbitol used in preparation of MN matrix samples.  
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